

CITATION REPORT

List of articles citing

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

DOI: 10.1182/blood.v89.6.2079
Blood, 1997, 89, 2079-2088.

Source: <https://exaly.com/paper-pdf/28466256/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2319	Perhaps not everyone knows that□1997, 8, 509-510		
2318	Chromosome 7 and Haematological Malignancies. 1997 , 2, 359-72		
2317	Haematology. The periphery is now central. 1997 , 350 Suppl 3, SIII9		
2316	International Prognostic Scoring System and Other Prognostic Systems for Myelodysplastic Syndromes. <i>Blood</i> , 1997 , 90, 4232-4235	2.2	10
2315	Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes. <i>Blood</i> , 1997 , 90, 1403-1409	2.2	222
2314	Application of the International Scoring System for Myelodysplasia to M.D. Anderson Patients. <i>Blood</i> , 1997 , 90, 2843-2845	2.2	39
2313	Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy. <i>Blood</i> , 1997 , 90, 2969-2977	2.2	189
2312	Etiopathogeny, prognosis and therapy of myelodysplastic syndromes. 1997 , 39, 277-94		12
2311	Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. 1997 , 99, 939-44		108
2310	Myelodysplastische Syndrome. 1998 , 39, 1168-1180		3
2309	RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. 1998 , 12, 887-92		188
2308	Increasing incidence of myelodysplastic syndromes: real or fictitious?. 1998 , 22, 93-100		67
2307	Problems in the classification of CMML--dysplastic versus proliferative type. 1998 , 22, 871-8		129
2306	Molecular features of primary MDS with cytogenetic changes. 1998 , 22, 293-302		25
2305	Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients. 1998 , 22 Suppl 1, S13-6		8
2304	Intensive therapy for high-risk myelodysplastic syndromes and the biological significance of karyotype abnormalities. 1998 , 22 Suppl 1, S23-6		5
2303	Risk factors and their relationship to prognosis in myelodysplastic syndromes. 1998 , 22 Suppl 1, S3-6		15

2302	Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. 1998 , 22, 767-77	53
2301	Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. 1998 , 22 Suppl 1, S41-7	25
2300	A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias. The Central Pennsylvania Oncology Group. 1998 , 22, 741-9	7
2299	The classification of chronic myelomonocytic leukaemia. 1998 , 22, 879-80	10
2298	Bone marrow transplantation for myelodysplasia in adults and children: when and who?. 1998 , 22 Suppl 1, S35-9	7
2297	Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. 1998 , 22, 1123-36	102
2296	Molecular genetics and cytogenetics of myeloproliferative disorders. 1998 , 11, 819-48	68
2295	Childhood myeloproliferative disorders. 1998 , 11, 875-98	3
2294	Sideroblastic anemias: variations on imprecision in diagnostic criteria, proposal for an extended classification of sideroblastic anemias. 1998 , 57, 1-6	15
2293	Simultaneous occurrence of lupus anticoagulant and factor VIII inhibitors in hemophilia. 1998 , 58, 248	2
2292	Polycythemia vera in a patient with acquired immunodeficiency syndrome. 1998 , 58, 248-9	3
2291	Prothrombin gene 20210 G-A mutation in the Turkish population. 1998 , 58, 249	61
2290	Elevated beta 2-microglobulin in lymphorrhea from immunoblastic lymphoma. 1998 , 58, 249-50	4
2289	Are sickle cell disease patients with stroke genetically predisposed to the event by inheriting a tendency to high tumor necrosis factor levels?. 1998 , 58, 250	4
2288	Usefulness of IPSS for the patients with refractory anemia. 1998 , 58, 250-2	10
2287	Vibrio vulnificus sepsis associated with coincidental diagnosis of acute myeloid leukemia. 1998 , 58, 252	0
2286	Myelodysplastic syndrome with erythroid hypoplasia/aplasia: a case report and review of the literature. 1998 , 58, 319-25	23
2285	Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes. 1998 , 102, 465-74	69

2284	Differentiation therapy of myelodysplastic syndromes: fact or fiction?. 1998 , 102, 1124-38		18
2283	A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. 1998 , 103, 176-88		194
2282	Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings. 1998 , 103, 189-97		60
2281	A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. 1998 , 103, 1070-4		156
2280	'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. 1998 , 103, 1075-82		82
2279	The myelodysplastic syndromes: towards a functional classification. 1998 , 12, 73-83		17
2278	Ultrastructural abnormalities of bone marrow erythroblasts in refractory anemia. 1998 , 22, 173-80		5
2277	Ploidy Analysis and Ki-67 Expression in Myelodysplastic Syndromes. 1998 , 3, 215-22		0
2276	High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene. 1998 , 32, 9-18		23
2275	Pathogenetic Aspects of Myelodysplastic Syndromes. 1998 , 3, 119-42		
2274	Diagnosis and Management of Anemia in Patients With the Myelodysplastic Syndrome. 1998 , 5, 41-45		1
2273	Methylation of the p15INK4b Gene in Myelodysplastic Syndromes Is Frequent and Acquired During Disease Progression. <i>Blood</i> , 1998 , 91, 2985-2990	2.2	302
2272	Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients. <i>Blood</i> , 1998 , 92, 68-75	2.2	247
2271	Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1998 , 92, 1910-1917	2.2	129
2270	Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. 1999 , 17, 2819-30		117
2269	Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. 1999 , 17, 3128-35		159
2268	Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes. 1999 , 17, 277-83		9
2267	Verlauf und Prognose. 1999 ,		

2266	Clinical features and diagnosis of Fanconi's anemia. 1999 , 319-337	
2265	Management of acute myeloid leukaemia following myelodysplastic syndrome in a kidney graft recipient. 1999 , 14, 501-6	3
2264	Marrow cytokine transcripts and the secondary hematologic disorders. 1999 , 35, 297-302	3
2263	Myelodysplasia. 1999 , 340, 1649-60	411
2262	Iron overload in patients with sideroblastic anaemia is not related to the presence of the haemochromatosis Cys282Tyr and His63Asp mutations. 1999 , 104, 97-9	16
2261	The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. 1999 , 104, 730-7	151
2260	Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology. Scandinavian MDS Group, Sweden and Norway. 1999 , 105, 966-73	11
2259	DNA image cytometry in MDS bone marrow smears. 1999 , 105, 960-5	2
2258	Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. 1999 , 106, 445-54	49
2257	Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. 1999 , 106, 455-63	64
2256	Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes. 1999 , 107, 844-50	39
2255	rHuEpo TREATMENT IN LOW-RISK MYELOYDYSPLASTIC SYNDROMES: A REPLY. 1999 , 106, 574	
2254	Significance of electron-dense deposits in the mitochondrial matrix of erythroid precursors in aplastic anaemia and myelodysplastic syndrome. 1999 , 105, 149-154	14
2253	Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. 1999 , 105, 141-148	37
2252	Haemopoietic reconstitution by donor-derived myelodysplastic progenitor cells after haemopoietic stem cell transplantation. 1999 , 105, 361-365	15
2251	The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. 1999 , 13, 393-9	158
2250	Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS). 1999 , 13, 376-85	121
2249	A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leuchémies aiguës myéloïdes. 1999 , 13, 524-9	45

2248	Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. 1999 , 13, 1009-12	28
2247	A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group. 1999 , 13, 1207-13	23
2246	Vitamin K2 induces apoptosis of a novel cell line established from a patient with myelodysplastic syndrome in blastic transformation. 1999 , 13, 1399-405	32
2245	Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes. 1999 , 13, 1554-63	47
2244	New system for assessing the prognosis of refractory anemia patients. 1999 , 13, 1727-34	17
2243	Angiogenesis in myelodysplastic syndromes. 1999 , 81, 1398-401	223
2242	Spontaneous remission in myelodysplastic syndrome. 1999 , 78, 89-90	6
2241	[Clinical course, morphology and prognosis of chronic myelomonocytic leukemia]. 1999 , 94, 467-72	2
2240	Frequency of trisomy 15 and loss of the Y chromosome in adult leukemia. 1999 , 114, 108-11	19
2239	HPRT mutations in vivo in human CD 34+ hematopoietic stem cells. 1999 , 431, 183-98	4
2238	Fitness landscapes and the myeloid leukemias. 1999 , 23, 167-76	10
2237	Myelodysplastic syndrome and associated skin lesions: a review of the literature. 1999 , 23, 323-30	104
2236	Myelodysplastic syndrome: a search for minimal diagnostic criteria. 1999 , 23, 283-90	55
2235	Identification of multiple copies of a 20q-chromosome in a case of myelodysplastic syndrome: a FISH study. 1999 , 23, 407-13	12
2234	Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study. 1999 , 23, 425-32	21
2233	Neutrophil dysplasia is not a specific feature of the abnormal chromosomal clone in myelodysplastic syndromes. 1999 , 23, 579-84	13
2232	Apoptosis and its significance in MDS: controversies revisited. 1999 , 23, 777-85	40
2231	Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. 1999 , 23, 811-5	5

2230	The prognostic value of in vitro cultures of erythroid and megakaryocyte progenitors in myelodysplastic syndromes. 1999 , 23, 889-94	15
2229	Cytogenetics. 1999 , 23, IN3-S12	
2228	Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome. 1999 , 26, 336-345	86
2227	The treatment of the myelodysplastic syndromes. 1999 , 86, 1893-9	3
2226	Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. 1999 , 86, 2006-2013	20
2225	Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. 1999 , 61, 66-77	18
2224	How shall we apply the new biology to diagnostics in surgical pathology?. 1999 , 187, 147-54	18
2223	Allogeneic hematopoietic stem cell transplantation for acute leukemia, chronic leukemia, and myelodysplasia. 1999 , 13, 987-1015, vi-vii	11
2222	Malignancy: Current Clinical Practice: Current Therapeutic Options in Myelodysplastic Syndromes. 1999 , 4, 91-112	0
2221	Application of the International Prognostic Scoring System for myelodysplastic syndromes. 1999 , 10, 825-9	26
2220	Concurrent inflammatory bowel disease and myelodysplastic syndromes. 1999 , 5, 98-103	29
2219	Specific cutaneous lesions of the scalp in myelodysplastic syndrome with deletion of 20q. 1999 , 26, 220-4	4
2218	Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. 2000 , 18, 956-62	502
2217	Pyoderma Gangrenosum and Myelodysplastic Syndrome. 2000 , 93, 923-925	7
2216	Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation. 2000 , 117, 503-12	64
2215	New Aspects of the Treatment of Patients with Low-Risk Myelodysplastic Syndromes. 2000 , 23, 12-16	1
2214	Hemopoietic stem cell transplantation for myelodysplastic syndrome. 2000 , 12, 116-20	10
2213	Cytokine therapy for myelodysplastic syndrome. 2000 , 7, 156-60	9

2212	Myelodysplasia. 2000 , 12, 13-21	21
2211	Myelodysplastic syndromes in children. A critical review of the clinical manifestations and management. 2000 , 63, 212-22	11
2210	Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia. 2000 , 108, 93-5	41
2209	Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica. 2000 , 108, 346-56	194
2208	Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. 2000 , 108, 724-8	51
2207	Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. 2000 , 109, 367-75	80
2206	Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. 2000 , 110, 217-22	31
2205	Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). 2000 , 110, 620-30	202
2204	Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. 2000 , 110, 584-90	32
2203	Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia. 2000 , 110, 847-55	16
2202	Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. 2000 , 14, 636-41	45
2201	Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. 2000 , 14, 1157-60	21
2200	Survival time in a population-based consecutive series of adult acute myeloid leukemia--the prognostic impact of karyotype during the time period 1976-1993. 2000 , 14, 1039-43	13
2199	Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan. 2000 , 14, 1156-7	34
2198	Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study. 2000 , 14, 1583-8	6
2197	Elevated MLF1 expression correlates with malignant progression from myelodysplastic syndrome. 2000 , 14, 1757-65	44
2196	Accommodating haploinsufficient tumor suppressor genes in Knudson's model. 2000 , 19, 3434-8	88
2195	Oncogene mutation and prognosis in the myelodysplastic syndromes. 2000 , 111, 873-874	1

2194	Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. 2000 , 28, 784-91	48
2193	Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes. 2000 , 28, 941-9	20
2192	Refractory anemia with ringed sideroblasts with a low IPSS score progressed rapidly with de novo appearance of multiple karyotypic abnormalities and into acute erythroleukemia (AML-M6A). 2000 , 24, 597-600	2
2191	Dyshaemopoiesis in adults: a practical classification for diagnosis and management. 2000 , 24, 641-51	3
2190	Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. 2000 , 24, 653-63	31
2189	Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. 2000 , 24, 839-48	62
2188	Dynamic cell cycle kinetics in vitro and in vivo in myelodysplastic syndromes with special reference to the influence of hematopoietic growth factors. 2000 , 24, 999-1008	1
2187	Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. 2000 , 24, 983-92	225
2186	Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry. 2000 , 24, 163-74	18
2185	Myelodysplastic syndrome at a large tertiary care community hospital: analysis according to the international prognostic scoring system. 2000 , 24, 417-26	7
2184	Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes. 2000 , 24, 109-15	17
2183	A novel dicentric deleted chromosome 21 arising from tandem translocation. 2000 , 121, 208-11	3
2182	Pentasomy 8 in pediatric myelodysplastic syndrome. 2000 , 121, 220-2	6
2181	Myelodysplastic syndrome and a nonrandom chromosomal abnormality t(1;19): an indolent pathologic entity. 2000 , 122, 134-6	2
2180	17p- syndrome arising from a novel dicentric translocation in a patient with acute myeloid leukemia. 2000 , 118, 159-62	8
2179	Bone marrow transplantation for myelodysplasia. 2000 , 14, 63-77	34
2178	Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia. 2000 , 14, 182-9	8
2177	Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia. 2000 , 2, 140-3	5

2176	Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. 2000 , 79, 255-8		19
2175	Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis. 2000 , 17, 16-21		11
2174	Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. <i>Blood</i> , 2000 , 95, 3273-3279	2.2	183
2173	Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. <i>Blood</i> , 2000 , 95, 1175-1179	2.2	82
2172	Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. <i>Blood</i> , 2000 , 95, 1188-1194	2.2	157
2171	The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. <i>Blood</i> , 2000 , 96, 3932-3938	2.2	267
2170	Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. <i>Blood</i> , 2000 , 96, 2012-2021	2.2	193
2169	The chromosomes can tell you what they're made of. <i>Blood</i> , 2000 , 96, 2021-2021	2.2	2
2168	Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. <i>Blood</i> , 2000 , 95, 2093-2097	2.2	56
2167	Defective megakaryocytic development in myelodysplastic syndromes. 2000 , 38, 13-9		23
2166	Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. 2000 , 18, 963-71		180
2165	Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. 2000 , 18, 3447-52		56
2164	Excessive apoptosis in low risk myelodysplastic syndromes (MDS). 2000 , 40, 1-24		35
2163	A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes. 2000 , 36, 485-96		12
2162	Achievements in Understanding and Treatment of Myelodysplastic Syndromes. 2000 , 2000, 110-132		16
2161	Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. 2000 , 37, 405-14		111
2160	Decline in antibiotic enzyme activity of neutrophils is a prognostic factor for infections in patients with myelodysplastic syndrome. 2000 , 31, 1292-5		9
2159	Association between nasal carriage of <i>Staphylococcus aureus</i> and infection in liver transplant recipients. 2000 , 31, 1295-9		61

2158	Comparative genomic hybridization study of de novo myeloid neoplasia. 2000 , 104, 25-30	10
2157	Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. 2000 , 67, 28-39	37
2156	Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?. 2000 , 37, 15-29	133
2155	The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes. 2000 , 9, 247-55	27
2154	Modern Hematology. 2000 ,	3
2153	SIGNIFICANCE OF MONOSOMY 7 IN MYELOID LEUKEMIAS IN CHILDREN. 2000 , 19, 235-250	0
2152	Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. 2000 , 18, 112-9	18
2151	The cytogenetics of myelodysplastic syndromes. 2001 , 14, 479-95	59
2150	Myeloproliferative disorders. 2001 , 14, 531-51	37
2149	Allogeneic transplantation for leukaemia using unrelated donors. 2001 , 14, 793-805	3
2148	Clinical syndromes of transformation in clonal hematologic disorders. 2001 , 111, 480-8	3
2147	Treatment of myelodysplastic syndromes. 2001 , 6, 74-9	2
2146	Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. 2001 , 7, 163-70	20
2145	Hematologic Abnormalities and Outcome of 16 Cats with Myelodysplastic Syndromes. 2001 , 15, 471-477	38
2144	[Iron overload and myelodysplastic syndromes]. 2001 , 8, 422-32	12
2143	Chronic myeloid disorders: Classification and treatment overview. 2001 , 38, 1-4	29
2142	Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes. 2001 , 357, 1059-60	7
2141	Síndromes mielodisplásicos. 2001 , 8, 2749-2754	

2140	Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. 2001 , 42, 291-9		41
2139	Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. 2001 , 19, 2134-41		72
2138	Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI. 2001 , 19, 3794		9
2137	Full-impact medicine. 2001 , 19, 3793-4		1
2136	Validation of the ucla integrated staging system for patients with renal cell carcinoma. 2001 , 19, 3792-3		47
2135	Successful electroconvulsive therapy in an elderly man with severe thrombocytopenia: case report and literature review. 2001 , 17, 198-200		5
2134	Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. <i>Blood</i> , 2001 , 98, 565-72	2.2	148
2133	Misleading information about ALIP and VEGF in myelodysplasia. <i>Blood</i> , 2001 , 98, 1272-3	2.2	3
2132	Myelodysplastic syndromes standardized response criteria: further definition. <i>Blood</i> , 2001 , 98, 1985	2.2	30
2131	Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. <i>Blood</i> , 2001 , 98, 2935-41	2,2	101
2130	Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. <i>Blood</i> , 2001 , 98, 3058-65	2.2	106
2129	Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. <i>Blood</i> , 2001 , 98, 3492-4	2.2	33
2128	Pseudo Pelger-Huët anomaly in myelodysplastic syndrome: hyposegmented apoptotic neutrophil?. <i>Blood</i> , 2001 , 98, 1273-5	2.2	25
2127	Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. <i>Blood</i> , 2001 , 98, 958-65	2.2	272
2126	Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays. <i>Blood</i> , 2001 , 98, 1914-21	2.2	31
2125	Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. <i>Blood</i> , 2001 , 98, 2332-8	2.2	202
2124	Classifying chronic myelomonocytic leukemia. 2001 , 19, 3790-2		3
2123	A decade of progress in allogeneic hematopoietic cell transplantation: 1990-2000. 2001 , 81, 1-59		1

2122	[Place of hematopoietic stem cell transplantation in the treatment of myelodysplastic syndromes]. 2001 , 96, 135-43	
2121	Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome. 2001 , 80, 53-7	3
2120	Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. 2001 , 80, 272-7	27
2119	Evolving treatment options of myelodysplastic syndromes. 2001 , 80, 499-509	8
2118	Treatment of myelodysplastic syndrome with low-dose human granulocyte colony-stimulating factor: a multicenter study. 2001 , 74, 144-6	6
2117	A variant form of myelodysplastic syndrome with Ph- minor-BCR/ABL transcript. 2001 , 74, 58-63	5
2116	Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. 2001 , 73, 405-410	67
2115	Chromosome and molecular abnormalities in myelodysplastic syndromes. 2001 , 73, 429-437	102
2114	Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. 2001 , 112, 714-26	47
2113	Molecular characterization of a myelodysplasia-associated chromosome 7 inversion. 2001 , 113, 143-52	8
2112	The prognostic impact of karyotypic subgroups in myelodysplastic syndromes is strongly modified by sex. 2001 , 113, 347-56	22
2111	Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. 2001 , 113, 763-71	148
2110	International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. 2001 , 115, 309-12	72
2109	The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. 2001 , 115, 881-94	84
2108	Primary myelodysplasia: management and outcome at 3 years in 45 patients age 65 and older. 2001 , 49, 1358-60	2
2107	Re-evaluation of refractory anemia with excess blasts in transformation. 2001 , 25, 933-9	13
2106	Acute myeloid leukemia in the elderly: biology and therapeutic strategies. 2001 , 39, 275-87	55
2105	Management of high-risk myelodysplastic syndromes. 2001 , 40, 215-28	6

2104	Myelodysplastic syndrome: review of the cytogenetic and molecular data. 2001 , 40, 229-38	42
2103	High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. 2001 , 92, 1999-2015	70
2102	Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study. 2001 , 66, 23-7	8
2101	Successful treatment of refractory anemia by high-dose methylprednisolone associated with an increment in CD68-positive cells in bone marrow. 2001 , 66, 80-4	2
2100	DNA content of granulocytes, monocytes, and lymphocytes in the bone marrow smears of patients with myelodysplastic syndromes. 2001 , 67, 112-8	
2099	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. 2001 , 67, 227-33	18
2098	Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia. 2001 , 15, 954-62	57
2097	Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. 2001 , 15, 950-3	38
2096	Prognostic evaluation of the microvascular network in myelodysplastic syndromes. 2001 , 15, 1369-76	70
2095	Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. 2001 , 15, 1713-20	80
2094	Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. 2001 , 15, 1841-7	77
2093	Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. 2001 , 15, 1878-84	28
2092	Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. 2001 , 114, 349-357	2
2091	Trisomy 14 in myeloid malignancies: report of two cases and review of the literature. 2001 , 124, 172-4	9
2090	Trisomy 15 as a single autosomal abnormality in a patient with unclassifiable myelodysplastic syndromes. 2001 , 127, 91-2	8
2089	Routine fluorescence in situ hybridization with the MLL probe does not reliably detect two separate signals on one chromosome 11 in patients with trisomy 11. 2001 , 129, 173-6	2
2088	Abnormal dicentric chromosome with co-amplification of sequences from chromosomes 11 and 19: a novel rearrangement in a patient with myelodysplastic syndrome transforming to acute myeloid leukemia. 2001 , 130, 29-32	3
2087	A new case of isolated del(12)(q15q22) in myelodysplastic syndrome. 2001 , 130, 89-91	

2086	The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. 2001 , 130, 160-5	48
2085	Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. 2001 , 25, 13-18	20
2084	Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?. 2001 , 25, 19-21	14
2083	Masked monosomy 7 in myelodysplastic syndromes is uncommon and of undetermined clinical significance. 2001 , 25, 197-203	14
2082	Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. 2001 , 25, 287-94	30
2081	Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis. 2001 , 25, 385-93	33
2080	Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution. 2001 , 25, 741-7	46
2079	Myelodysplasia with fibrosis: a distinct entity?. 2001 , 25, 829-38	44
2078	Refractory anemia with excess of blasts in transformation: a dying category?. 2001 , 25, 1095-6	2
2077	Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. 2001 , 114, 349-57	207
2076	Myelodysplastic syndrome and pregnancy: the Mayo Clinic experience. 2001 , 42, 1229-34	2
2075	Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). 2001 , 6 Suppl 5, 8-14	86
2074	Intravenous bolus topotecan in patients with myelodysplastic syndrome. 2001 , 42, 963-8	2
2073	Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. 2002 , 11, 119-25	60
2072	The World Health Organization (WHO) classification of the myeloid neoplasms. <i>Blood</i> , 2002 , 100, 2292-302	1637
2071	Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. <i>Blood</i> , 2002 , 100, 1201-7	2.2 253
2070	Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia. 2002 , 32, 169-73	8
2069	Levels of circulating endothelial adhesion molecules in patients with myelodysplastic syndromes. 2002 , 20, 167	4

2068	A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. 2002 , 24, 596-605		42
2067	Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. 2002 , 16, 310-5		15
2066	Chromosome 11q deletion in myeloid malignancies. 2002 , 16, 953-5		9
2065	Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients. 2002 , 16, 623-31		18
2064	Myelodysplastic syndromes. 2002 , 2002, 136-61		107
2063	Thalidomide for the treatment of patients with myelodysplastic syndromes. 2002 , 16, 1-6		125
2062	Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. 2002 , 16, 162-4		83
2061	De novo appearance of t(7;13)(q10;q33) in the leukemic phase of myelodysplastic syndrome: a case report. 2002 , 32, 35-6		2
2060	New approaches to the treatment of myelodysplasia. 2002 , 7 Suppl 1, 39-49		48
2059	Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. <i>Blood</i> , 2002 , 100, 259-67	2.2	137
2058	A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. 2002 , 24, 343-52		15
2057	Expansion of trisomy 8 and Sweet syndrome in a prolonged course of aplastic anemia. 2002 , 24, 64-8		9
2056	Proposed changes in the definitions of acute myeloid leukemia and myelodysplastic syndrome: are they helpful?. 2002 , 14, 19-23		17
2055	Prognosis of hematologic malignancies does not predict intensive care unit mortality. 2002 , 30, 2260-70		643
2054	A new aspect of the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria. 2002 , 7, 211-27		8
2053	Myelodysplasia and the acute myeloid leukaemias. 2002 , 7, 325-38		1
2052	Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. <i>Blood</i> , 2002 , 100, 3553-60	2.2	197
2051	Myelodysplastic syndrome is not merely "preleukemia". <i>Blood</i> , 2002 , 100, 791-8	2.2	109

2050	Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. <i>Blood</i> , 2002 , 100, 2957-64	2.2	459
2049	Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. <i>Blood</i> , 2002 , 99, 4370-8	2.2	124
2048	Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. <i>Blood</i> , 2002 , 99, 840-9	2.2	304
2047	Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. <i>Blood</i> , 2002 , 99, 1578-84	2.2	41
2046	Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. <i>Blood</i> , 2002 , 99, 1909-12		204
2045	Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. <i>Blood</i> , 2002 , 99, 1943-51	2.2	190
2044	Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. <i>Blood</i> , 2002 , 99, 3074-5	2.2	21
2043	Myelodysplastic syndromes: prognostic significance of multilineage dysplasia in patients with refractory anemia or refractory anemia with ringed sideroblasts. <i>Blood</i> , 2002 , 99, 3870-1; author reply 3871	2.2	14
2042	Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. <i>Blood</i> , 2002 , 100, 3887-96	2.2	155
2041	Immunophenotypic clustering of myelodysplastic syndromes. <i>Blood</i> , 2002 , 100, 2349-56	2.2	97
2040	Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. <i>Blood</i> , 2002 , 100, 2243-5	2.2	152
2039	Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. 2002 , 137, 156-63		164
2038	Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin m, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia. 2002 , 20, 154-62		8
2037	Myelodysplastic Syndrome. 2002 , 1, 301-311		1
2036	Apoptosis and prognostic factors in myelodysplastic syndromes. 2002 , 43, 257-60		12
2035	Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. <i>Blood</i> , 2002 , 99, 3129-35	2.2	192
2034	Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia. 2002 , 43, 275-80		24
2033	Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. 2002 , 8, 435-43		26

2032	Myelodysplastic syndrome overview. 2002 , 39, 18-25		42
2031	Thalidomide in myelodysplastic syndromes. 2002 , 56, 20-30		7
2030	Response to erythropoietin and moxifloxacin in a patient with myelodysplastic syndrome non-respondent to erythropoietin alone. 2002 , 13, 521-523		5
2029	[Prognostic factors in myelodysplasia syndromes]. 2002 , 50, 256-60		
2028	[New WHO classification of myelodysplastic syndromes. The consequences]. 2002 , 50, 278-82		3
2027	Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. 2002 , 20, 2429-40		1478
2026	HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. <i>Blood</i> , 2002 , 100, 1570-1574	2.2	202
2025	Granulocytic sarcoma: case report with an unusual presentation and review of the literature. 2002 , 60, 1206-11		22
2024	Cytogenetic survey of 117 Tunisian patients with de novo myelodysplastic syndrome. 2002 , 45, 131-5		1
2023	Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation. 2002 , 68, 345-53		18
2022	Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. 2002 , 68, 180-5		37
2021	Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells. 2002 , 30, 318-23		29
2020	Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin. 2002 , 70, 92-9		27
2019	Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. 2002 , 70, 115-25		46
2018	Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome. 2002 , 71, 166-71		40
2017	Molecular cytogenetic aspects of hematological malignancies: clinical implications. 2002 , 115, 130-41		38
2016	Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. 2002 , 33, 413-23		40
2015	Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. 2002 , 75, 289-97		68

2014	Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis. 2002 , 76 Suppl 2, 29-34	13
2013	Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma. 2002 , 76 Suppl 2, 65-74	9
2012	Important features of myelodysplastic syndrome. 2002 , 76 Suppl 2, 222-7	10
2011	The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002). 2002 , 76 Suppl 2, 228-38	27
2010	Chronic myelomonocytic leukemia. 2002 , 3, 221-3	10
2009	Older adults with acute myeloid leukemia. 2002 , 4, 403-9	8
2008	[Myelodysplastic syndromes. Diagnosis and therapeutic strategies]. 2002 , 97, 666-76	10
2007	Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response. 2002 , 81, 182-6	5
2006	Splenectomy in patients with mixed myelodysplastic/myeloproliferative disease. 2002 , 81, 308-11	4
2005	Evaluating the prognosis of patients with myelodysplastic syndromes. 2002 , 81, 485-97	30
2004	Assessment of growth and differentiation processes in myelodysplastic syndromes by PCR analysis of Galpha16 and 5'-lipoxygenase. 2002 , 81, 632-40	2
2003	Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. 2002 , 128, 497-502	20
2002	Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. 2002 , 116, 334-337	26
2001	Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99. 2002 , 117, 33-9	39
2000	A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. 2002 , 117, 119-26	52
1999	Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). 2002 , 118, 67-73	82
1998	Treatment responses of childhood aplastic anaemia with chromosomal aberrations at diagnosis. 2002 , 118, 313-9	20
1997	Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. 2002 , 118, 174-80	90

1996	Prognosis of myelodysplastic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. 2002 , 119, 87-96	11
1995	Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. 2002 , 119, 144-54	67
1994	Does isochromosome 7q mandate bone marrow transplant in children with Shwachman-Diamond syndrome?. 2002 , 119, 1062-9	38
1993	Erythroleukemia: a comparison between the previous FAB approach and the WHO classification. 2002 , 26, 423-9	25
1992	Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. 2002 , 26, 721-4	38
1991	FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. 2002 , 26, 725-30	38
1990	Bone marrow transplantation for myelodysplastic syndrome--who? when? and which?. 2002 , 30, 199-206	15
1989	Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes. 2002 , 16, 1680-4	64
1988	Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. 2002 , 16, 1615-21	52
1987	Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. 2002 , 16, 2177-84	45
1986	Telomeres and telomerase in hematologic neoplasia. 2002 , 21, 680-7	129
1985	Bone marrow lymphoid aggregates in myelodysplastic syndromes: incidence, immunomorphological characteristics and correlation with clinical features and survival. 2002 , 26, 525-30; discussion 531	12
1984	Treatment of myelodysplastic syndromes with 5-azacytidine. 2002 , 26, 893-7	45
1983	Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. 2002 , 26, 993-6	53
1982	Biological and clinical significance of clonogenic assays in patients with myelodysplastic syndromes. 2002 , 19, 249-59	14
1981	Oxidative stress and the myelodysplastic syndromes. 2003 , 77, 342-50	80
1980	Two cases of acute myeloblastic leukemia evolving from aplastic anemia. 2003 , 77, 471-5	1
1979	Successful aortic valve replacement in severe pancytopenia related to myelodysplastic syndrome. 2003 , 51, 77-80	6

1978	Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). 2003 , 115, 515-36	4
1977	Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes. 2003 , 82, 271-7	11
1976	Successful treatment of pyoderma gangrenosum that developed in a patient with myelodysplastic syndrome. 2003 , 9, 268-71	12
1975	A unique clone involving multiple structural chromosome rearrangements in a myelodysplastic syndrome case. 2003 , 140, 138-44	5
1974	Is monosomy 5 an uncommon aberration? Fluorescence in situ hybridization reveals translocations and deletions in myelodysplastic syndromes or acute myelocytic leukemia. 2003 , 142, 107-14	16
1973	Determination of cutoff values to detect small aneuploid clones by interphase fluorescence in situ hybridization: the Poisson model is a more appropriate approach. Should single-cell trisomy 8 be considered a clonal defect?. 2003 , 147, 99-109	10
1972	Apoptotic rate in patients with myelodysplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines. 2003 , 7, 313-21	3
1971	Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin. 2003 , 72, 220-2	14
1970	Evidence for expression of early myeloid antigens in mature, non-blast myeloid cells in myelodysplasia. 2003 , 74, 9-16	15
1969	A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q-syndrome from refractory anemia in primary myelodysplastic syndrome. 2003 , 27, 221-9	43
1968	The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. 2003 , 27, 95-120	125
1967	Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?. 2003 , 27, 235-42	54
1966	Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. 2003 , 27, 783-8	53
1965	7th International Symposium on Myelodysplastic. 2003 , 27, 1-123	2
1964	Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. 2003 , 27, 1085-90	63
1963	Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. 2003 , 120, 187-200	211
1962	A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. 2003 , 120, 679-84	108
1961	A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. 2003 , 120, 1037-46	322

1960	A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. 2003 , 120, 960-9	58
1959	Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. 2003 , 121, 758-67	103
1958	Therapy-related myelodysplasia and/or acute myeloid leukaemia after autologous haematopoietic progenitor cell transplantation in a prospective single centre cohort of 221 patients. 2003 , 122, 109-17	16
1957	The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups. 2003 , 123, 81-9	15
1956	Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate. 2003 , 123, 366-7	2
1955	Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes. 2003 , 123, 879-85	19
1954	Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry. 2003 , 32, 987-92	23
1953	Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. 2003 , 32, 1071-5	11
1952	Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts. 2003 , 17, 319-22	8
1951	A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. 2003 , 17, 277-82	346
1950	Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. 2003 , 17, 305-13	87
1949	Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. 2003 , 17, 1200-2	23
1948	The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). 2003 , 17, 859-68	34
1947	Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. 2003 , 17, 1499-507	99
1946	No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. 2003 , 17, 1827-33	30
1945	DNA microarray analysis of hematopoietic stem cell-like fractions from individuals with the M2 subtype of acute myeloid leukemia. 2003 , 17, 1990-7	20
1944	Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. 2003 , 17, 2107-12	57
1943	Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. 2003 , 27, 397-404	32

1942	NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. 2003 , 27, 425-36	49
1941	MDS--new classification, new problem?. 2003 , 27, 567-9	4
1940	Farnesyl transferase inhibitors in myeloid malignancies. 2003 , 17, 123-9	20
1939	Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is "when?". 2003 , 78, 941-3	1
1938	The myelodysplastic/myeloproliferative disorders: the interface. 2003 , 17, 1095-100, v	13
1937	Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. 2003 , 78, 981-90	2
1936	Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromes. 2003 , 17, 1129-49	15
1935	The role of erythropoietin in the anemia of myelodysplastic syndrome. 2003 , 4 Suppl 1, S36-40	12
1934	The prognostic significance of antigen expression in leukaemia. 2003 , 16, 613-28	25
1933	Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. 2003 , 9, 753-9	29
1932	New insights into the physiology and treatment of acquired myelodysplastic syndromes and aplastic pancytopenia. 2003 , 33, 1317-34	13
1931	[Biologic and clinical relevance of cytogenetic analysis in primary myelodysplastic syndromes]. 2003 , 51, 346-55	2
1930	Genetic and molecular genetic studies in the diagnosis of myeloid diseases. 2003 , 34, 306-13	1
1929	Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. 2003 , 20, 154-79	15
1928	Diagnostic application of FISH to hematological malignancies. 2003 , 21, 807-14	7
1927	Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. <i>Blood</i> , 2003 , 102, 3052-9	2.2 153
1926	Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome. 2003 , 44, 915-22	41
1925	Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. 2003 , 21, 3060-5	55

1924	Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. 2003 , 21, 1988-95			125
1923	Transplantation in Hematology and Oncology II. 2003 ,			
1922	Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. 2003 , 21, 273-82			48
1921	Understanding the pathogenesis of myelodysplastic syndromes. 2003 , 4, 303-9			26
1920	Hematologic Malignancies. 2003 , 487-506			
1919	Immunosuppressive treatments for myelodysplastic syndromes. 2003 , 44, 593-604			17
1918	Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis. 2003 , 44, 653-8			24
1917	Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders. 2003 , 78, 981-990			15
1916	Allogeneic Stem Cell Transplantation for Chronic Myeloproliferative Disorders and Myelodysplastic Syndromes: The Question Is When? 2003 , 78, 941-943			12
1915	Myelodysplastic syndrome. 2003 , 2003, 176-99			37
1914	Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. <i>Blood</i> , 2003 , 101, 1080-6	2.2		106
1913	Mitochondrial DNA mutations in patients with myelodysplastic syndromes. <i>Blood</i> , 2003 , 101, 3118-25	2.2		68
1912	Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. <i>Blood</i> , 2003 , 102, 394-403	2.2		269
1911	Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). <i>Blood</i> , 2003 , 102, 1622-5	2.2		25
1910	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. <i>Blood</i> , 2003 , 102, 4527-34	2.2		117
1909	Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. <i>Blood</i> , 2003 , 102, 1997-2003	2.2		122
1908	Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. <i>Blood</i> , 2003 , 102, 820-6	2.2		172
1907	Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. <i>Blood</i> , 2003 , 101, 4711-3	2.2		69

1906	Molecular characterization of the recurrent unbalanced translocation der(1;7)(q10;p10). <i>Blood</i> , 2003 , 102, 2597-604	2.2	29
1905	Treating patients of myelodysplastic syndrome with antithymocytic globulin--should we be more selective?. <i>Blood</i> , 2003 , 102, 3851-2; author reply 3852	2.2	3
1904	Continuous flow leukapheresis induces expression of stress genes in lymphocytes: impact on microarray analyses. <i>Blood</i> , 2003 , 102, 3852-3	2.2	7
1903	Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. <i>Blood</i> , 2003 , 101, 3386-90	2.2	73
1902	Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. <i>Blood</i> , 2003 , 101, 2156-8	2.2	83
1901	Leukemia, myelodysplastic syndrome and myeloproliferative disorder. 2003 , 317-330		
1900	Classification, treatment goals, and management principles for myelodysplastic syndromes. 2004 , 11, 3-6		3
1899	Telomere biology of human hematopoietic stem cells. 2004 , 11, 77-85		17
1898	Therapeutic spectrum in the treatment of myelodysplastic syndromes. 2004 , 5, 2451-8		1
1897	Myelodysplastic syndromes. 2004 , 2004, 297-317		93
1896	Myelodysplastic syndromes. 2004 , 5, 1-8		45
1895	Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. 2004 , 45, 2409-17		25
1894	Granulocytic sarcoma of the ovotestis: an association of myelodysplastic syndrome and hermaphroditism. 2004 , 45, 1285-7		7
1893	Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). 2004 , 22, 1078-86		198
1892	Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. 2004 , 22, 3751-7		593
1891	The myelodysplastic syndromes: a matter of life or death. 2004 , 111, 78-99		29
1890	Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing. 2004 , 15, 1684-90		21
1889	Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. 2004 , 63, 578-82		35

1888	Clinical implications of advanced molecular cytogenetics in cancer. 2004 , 4, 71-81	16
1887	Strategies for the laboratory diagnosis of some common causes of anaemia in elderly patients. 2004 , 50, 49-56	22
1886	CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. 2004 , 10, 7599-606	27
1885	Models of granulocyte DNA structure are highly predictive of myelodysplastic syndrome. 2004 , 101, 5008-11	14
1884	Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. 2004 , 172, 1960-9	57
1883	Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. 2004 , 22, 1287-92	124
1882	Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. 2004 , 43, 626-32	81
1881	Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q-). 2004 , 125, 337-42	26
1880	Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. 2004 , 125, 576-83	65
1879	Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. 2004 , 34, 690-700	71
1878	Monitoring treatment efficiency in MDS at the molecular level; possibilities now and in the future. 2004 , 28, 101-8	8
1877	Protein 4.1 deficiency and deletion of chromosome 20q are associated with acquired elliptocytosis in myelodysplastic syndrome. 2004 , 26, 69-72	14
1876	Autologous del(20q)-positive erythroid progenitor cells, re-emerging after DLI treatment of an MDS patient relapsing after allo-SCT, can provide a normal peripheral red blood cell count. 2004 , 33, 559-63	1
1875	Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. 2004 , 18, 113-9	163
1874	A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. 2004 , 18, 460-5	116
1873	Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. 2004 , 18, 466-75	126
1872	CD34+ progenitors from MDS patients are unresponsive to SDF-1, despite high levels of SDF-1 in bone marrow plasma. 2004 , 18, 1038-40	21
1871	Erythroleukaemia and RAEB-t: a same disease?. 2004 , 18, 888-90	13

1870	The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). 2004 , 18, 2008-14	75
1869	Clinical and morphological features of paediatric myelodysplastic syndromes: a review of 34 cases. 2004 , 93, 1015-23	15
1868	Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. 2004 , 73, 85-92	10
1867	Clinical, haematological and histomorphological profile of adult myelodysplastic syndrome. Study of 96 cases in a single institute. 2004 , 73, 93-7	15
1866	Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings. 2004 , 73, 351-8	27
1865	Update on myelodysplastic syndromes: new approaches to classification and therapy. 2004 , 31, 72-9	6
1864	Inversion of chromosome 12 and lineage promiscuity in hematologic malignancies. 2004 , 148, 91-103	1
1863	Heterogeneity of structural abnormalities in the 7q31.3 approximately q34 region in myeloid malignancies. 2004 , 150, 136-43	11
1862	Is fluorescence in situ hybridization a useful method in diagnosis of polycythemia vera patients?. 2004 , 151, 139-45	12
1861	Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics. 2004 , 152, 29-41	35
1860	Cytogenetic profile of myelodysplastic syndromes with complex karyotypes: an analysis using spectral karyotyping. 2004 , 153, 39-47	24
1859	Focus on myeloproliferative diseases and myelodysplastic syndromes. 2004 , 6, 547-52	77
1858	Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance. 2004 , 21, 325-31	16
1857	Long-term survivors in myelodysplastic syndromes: clinical and biological characteristics. 2004 , 21, 333-8	3
1856	May-Hegglin anomaly developing myelodysplasia and acute myeloid leukemia. 2004 , 79, 505-6	3
1855	Response to cyclosporine therapy in patients with myelodysplastic syndrome: a clinical study of 12 cases and literature review. 2004 , 80, 35-42	7
1854	Beyond genetics--the emerging role of epigenetic changes in hematopoietic malignancies. 2004 , 80, 120-7	8
1853	Pattern of ¹¹¹ In-chloride bone marrow scintigraphy in myelodysplastic syndrome; comparison with clinical characteristics. 2004 , 18, 675-80	2

1852	Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. 2004 , 35, 857-63	12
1851	Partial splenic embolization in myelodysplastic syndrome associated with immune thrombocytopenia. 2004 , 18, 213-6	1
1850	Absence of MLL gene rearrangement in de novo myelodysplastic syndromes (MDS). 2004 , 83, 170-5	7
1849	Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. 2004 , 83, 498-503	42
1848	Classification of refractory anemia. 2004 , 28, 213; discussion 215	
1847	Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics. 2004 , 28, 171-7	15
1846	Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. 2004 , 124, 26-32	47
1845	Genomic instability in bone marrow failure syndromes. 2004 , 76, 220-4	16
1844	Centrosome amplification and aneuploidy in bone marrow failure patients. 2004 , 40, 329-33	13
1843	MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q). 2004 , 41, 223-31	23
1842	Novel therapies for myelodysplastic syndromes. 2004 , 101, 226-41	41
1841	Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. 2004 , 101, 989-98	36
1840	Immunophenotyping of acute leukemias and myelodysplastic syndromes. 2004 , 58, 62-71	66
1839	Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. 2004 , 28, 325-32	56
1838	Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. 2004 , 28, 443-6	1
1837	Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. 2004 , 28, 551-7	16
1836	Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype. 2004 , 28, 651-5	6
1835	Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. 2004 , 28, 587-94	51

1834	The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. 2004 , 28, 785-90		72
1833	Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?. 2004 , 28, 1013-21		59
1832	Limited numbers of apoptotic cells in fresh paraffin embedded bone marrow samples of patients with myelodysplastic syndrome. 2004 , 28, 921-5		9
1831	Association between phenotypic features of blasts and the blast percentage in bone marrow of patients with myelodysplastic syndromes. 2004 , 28, 1171-5		13
1830	Complex cytogenetics in a case of probably work related MDS/AML. 2004 , 28, 1357-61		1
1829	Haematopoietic stem cell transplantation: indications, clinical developments and future directions. 2004 , 5, 97-108		9
1828	Remicade as TNF suppressor in patients with myelodysplastic syndromes. 2004 , 45, 2099-104		52
1827	Evaluation of temozolomide in patients with myelodysplastic syndrome. 2004 , 45, 1209-14		3
1826	Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome. 2004 , 45, 301-8		14
1825	Evolution of clonal cytogenetic abnormalities in aplastic anemia. 2004 , 45, 433-40		63
1824	WT1 gene transcript assay for relapse in acute leukemia after transplantation. 2004 , 45, 1747-53		15
1823	Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?. 2004 , 28, 1013-1013		
1822	[Applications of molecular biology to care of patients with malignant hematological disease]. 2004 , 62, 401-20		1
1821	Acute panmyelosis with myelofibrosis: clinical, immunophenotypic and cytogenetic study of twelve cases. 2004 , 45, 1873-9		23
1820	Risk assessment in chronic myelomonocytic leukemia (CMML). 2004 , 45, 1311-8		106
1819	Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. 2004 , 5, 227-33		25
1818	Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. <i>Blood</i> , 2004 , 104, 1616-23	2.2	179
1817	Pediatric Bone Marrow. 2004 ,		5

1816	[Recommendations for the cytogenetic management of myelodysplastic syndrome by the French Group fo Cytogenetic Hematology]. 2004 , 52, 245-7		1
1815	Myelodysplastic disorders. 2004 , 32, 61-64		0
1814	Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. 2004 , 41, 6-12		51
1813	Syndromes mielodisplásicos. 2004 , 9, 1325-1331		
1812	Molecular cytogenetic studies for hematological malignancies. 2004 , 121, 69-112		7
1811	State of the science for myelodysplastic syndrome: prognosis and promise of new therapies. 2004 , 17, 535-541		2
1810	Pathobiology, classification, and diagnosis of myelodysplastic syndrome. 2004 , 17, 543-557		48
1809	Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. 2004 , 17, 573-584		5
1808	Inhibitors of signaling in myelodysplastic syndrome. 2004 , 17, 613-622		2
1807	Apoptosis susceptibility and cell-cycle distribution in cells from myelodysplastic syndrome patients: modulatory in-vitro effects of G-CSF and interferon-alpha. 2004 , 45, 1437-43		1
1806	Flow cytometry for diagnosis and assessment of prognosis in patients with myelodysplastic syndromes. 2004 , 9, 171-7		24
1805	Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications. 2004 , 15, 189-201		2
1804	Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. <i>Blood</i> , 2004 , 104, 857-64	2.2	358
1803	The WHO classification of MDS does make a difference. <i>Blood</i> , 2004 , 103, 3265-70	2.2	117
1802	The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. <i>Blood</i> , 2004 , 103, 2908-13	2.2	94
1801	Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. <i>Blood</i> , 2004 , 104, 1266-9	2.2	229
1800	Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. <i>Blood</i> , 2004 , 104, 4210-8	2.2	132
1799	A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. <i>Blood</i> , 2004 , 104, 579-85	2.2	535

1798	Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. <i>Blood</i> , 2004 , 104, 1474-81	2.2	113
1797	Organisation of neoplastic haematopathology services: a UK perspective. 2005 , 37, 479-92		7
1796	Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes. 2005 , 2, 348-55		3
1795	Gene expression profiling in the myelodysplastic syndromes. 2005 , 10, 281-7		11
1794	Profile of azacitidine. 2005 , 2, 717-731		2
1793	Decitabine in myelodysplastic syndromes. 2005 , 2, 835-842		3
1792	Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. <i>Blood</i> , 2005 , 105, 3472-9	2.2	41
1791	Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. <i>Blood</i> , 2005 , 105, 443-52	2.2	78
1790	Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. <i>Blood</i> , 2005 , 106, 803-11	2.2	171
1789	Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. <i>Blood</i> , 2005 , 106, 247-53	2.2	86
1788	Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. <i>Blood</i> , 2005 , 106, 2633-40	2.2	81
1787	Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. <i>Blood</i> , 2005 , 106, 2982-91	2.2	107
1786	Erythropoietin for the anemia of low-risk myelodysplastic syndromes. <i>Blood</i> , 2005 , 106, 768-769	2.2	4
1785	Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. <i>Blood</i> , 2005 , 106, 2912-9	2.2	1907
1784	Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. <i>Blood</i> , 2005 , 105, 4035-42	2.2	45
1783	NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. <i>Blood</i> , 2006 , 107, 1156-65	2.2	116
1782	Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. 2005 , 29, 41-6		34
1781	Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. 2005 , 29, 33-9		8

1780	A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals. 2005 , 29, 365-70	22
1779	Therapy-related myelodysplastic syndrome in childhood: a retrospective study of 36 patients in Japan. 2005 , 29, 625-32	19
1778	Myelodysplastic syndromes in patients under 50 years old: a single institution experience. 2005 , 29, 749-54	19
1777	Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. 2005 , 29, 987-93	18
1776	Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. 2005 , 29, 1217-9	60
1775	Telomerase activity in myelodysplastic syndromes. 2005 , 29, 1131-9	27
1774	Management of patients with higher risk myelodysplastic syndromes. 2005 , 56, 179-92	19
1773	Hypocellular myelodysplastic syndromes: clinical and biological significance. 2005 , 22, 169-75	24
1772	Spontaneous remission in adults with primary myelodysplastic syndromes: incidence and characteristics of patients. 2005 , 22, 407-10	8
1771	Assessment of the international prognostic scoring system for determining chemotherapeutic indications in myelodysplastic syndrome: Japanese retrospective multicenter study. 2005 , 82, 236-42	0
1770	Unrelated cord blood transplantation after myeloablative conditioning for adult patients with refractory anemia. 2005 , 81, 424-7	6
1769	Myelodysplastic syndrome. 2005 , 82, 412-6	1
1768	Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome. 2005 , 82, 66-71	3
1767	Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. 2005 , 128, 204-9	81
1766	Increased AF1q gene expression in high-risk myelodysplastic syndrome. 2005 , 128, 218-20	23
1765	SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. 2005 , 129, 791-4	19
1764	188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. 2005 , 130, 604-13	84
1763	Azacitidine. 2005 , 4, 275-6	109

1762	Stem cell transplantation from identical twins in patients with myelodysplastic syndromes. 2005 , 35, 37-43	12
1761	Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. 2005 , 19, 268-74	42
1760	Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. 2005 , 19, 396-401	97
1759	Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. 2005 , 19, 776-83	94
1758	Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. 2005 , 19, 767-75	95
1757	Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. 2005 , 19, 1424-31	62
1756	Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis. 2005 , 19, 1558-66	18
1755	Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. 2005 , 19, 1929-33	29
1754	A microRNA cluster as a target of genomic amplification in malignant lymphoma. 2005 , 19, 2013-6	177
1753	Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). 2005 , 19, 2223-31	131
1752	Deletion of the inositide-specific phospholipase c beta1 gene is a rare event in myelodysplastic syndrome and thus of limited value to predict leukemic progression. 2005 , 19, 2011-3	4
1751	Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. 2005 , 24, 2441-8	63
1750	Immunophenotyping of Myelodysplasia. 2005 , 5, 133-148	4
1749	Genotoxicity and sister chromatid exchange in patients with myelodysplastic disorders. 2005 , 159, 148-50	4
1748	Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases. 2005 , 160, 97-119	16
1747	Prognostic significance of del(20q) in patients with hematological malignancies. 2005 , 160, 188-92	29
1746	Programmed cell death is an intrinsic feature of MDS progenitors, predominantly found in the cluster-forming cells. 2005 , 33, 435-42	12
1745	Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS). 2005 , 32, S11-5	54

1744	Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients. 2005 , 32, S16-23	8
1743	Introduction. 2005 , 32, 1-2	
1742	Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). 2005 , 32, S31-5	29
1741	A comparative review of classification systems in myelodysplastic syndromes (MDS). 2005 , 32, S3-10	48
1740	Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome. 2005 , 25, 765-8	16
1739	Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study. 2005 , 42, 358-71	42
1738	Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array. 2005 , 42, 287-98	35
1737	Chronic myelomonocytic leukemia: lost in classification?. 2005 , 23, 26-33	29
1736	Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. 2005 , 104, 1656-60	52
1735	Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. 2005 , 104, 2717-25	142
1734	Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. 2005 , 64, 9-17	53
1733	Association of idiopathic thrombocytopenic purpura, in Klinefelter syndrome, that responded to cyclosporine administration. 2005 , 78, 316	
1732	Autoimmune thrombocytopenic purpura and Helicobacter pylori infection effectivity during childhood. 2005 , 78, 318	16
1731	Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. 2005 , 78, 317-8	20
1730	Methadone-related Torsades de Pointes in a sickle cell patient treated for chronic pain. 2005 , 78, 316-7	17
1729	Paracentric inversion of chromosome 12 in myelodysplasia. 2005 , 78, 318-9	1
1728	Flow-cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. 2005 , 79, 243-5	18
1727	Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: retrospective analysis of 21 cases. 2005 , 79, 329-31	13

1726	Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. 2005 , 54, 953-70	30
1725	Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes. 2005 , 84, 383-8	13
1724	In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. 2005 , 84 Suppl 1, 32-8	24
1723	Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. 2005 , 84 Suppl 1, 39-46	67
1722	An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. 2005 , 84 Suppl 1, 9-17	91
1721	Clinical experience with decitabine in North American patients with myelodysplastic syndrome. 2005 , 84 Suppl 1, 18-24	7
1720	Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. 2005 , 84 Suppl 1, 61-6	138
1719	The hematopathological basis for studying effects of the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in myelodysplasia. 2005 , 84 Suppl 1, 67-79	5
1718	Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. 2005 , 84, 389-94	23
1717	Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). 2005 , 84, 429-33	48
1716	Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. 2005 , 84, 569-71	61
1715	Ocular complications in myelodysplastic syndromes as preleukemic disorders. 2005 , 49, 377-83	14
1714	Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients. 2005 , 5, 55-9	18
1713	Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS). 2005 , 28, 654-660	3
1712	Clinical and prognostic characterization of myelodysplastic syndromes. 2005 , 1-32	
1711	Morphologic classifications of myelodysplastic syndromes: French-American-British (FAB) and World Health Organization (WHO). 2005 , 33-62	
1710	Pathogenetic mechanisms underlying myelodysplastic syndromes. 2005 , 63-94	1
1709	Cytogenetic abnormalities in myelodysplastic syndromes. 2005 , 95-128	1

1708	Molecular mechanisms and gene expression patterns in myelodysplastic syndromes. 2005 , 129-146	
1707	Biologically targeted therapies for myelodysplastic syndromes. 2005 , 173-208	
1706	Supportive care in myelodysplastic syndromes: hemopoietic cytokine and iron chelation therapy. 2005 , 209-242	1
1705	Hematopoietic cell transplantation for myelodysplastic syndromes. 2005 , 243-262	
1704	Health-related quality of life for those with myelodysplastic syndrome: conceptualization, measurement, and implications for research and practice. 2005 , 263-296	1
1703	Blood and Bone Marrow: Myeloid Leukaemias and Related Neoplasms. 2005 ,	
1702	Azacitidine: a novel agent for myelodysplastic syndromes. 2005 , 62, 1567-73	13
1701	Advances in myelodysplastic syndrome: nursing implications of azacitidine. 2005 , 9, 417-23	2
1700	Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. 2005 , 2 Suppl 1, S12-23	55
1699	Azacitidine. 2005 , Suppl, S6-7	43
1698	Efficacy of lenalidomide in myelodysplastic syndromes. 2005 , 352, 549-57	712
1697	Successful use of haploidentical stem-cell transplantation with KIR mismatch as initial therapy for poor-risk myelodysplastic syndrome. 2005 , 23, 4473-4	13
1696	Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia. 2005 , 11, 1821-6	20
1695	Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. 2005 , 23, 3439-46	96
1694	Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. 2005 , 23, 7594-603	678
1693	Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. 2005 , 16, 1921-7	72
1692	Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. 2005 , 2005, 161-6	19
1691	Myeloblast Phenotypic Changes in Myelodysplasia. 2005 , 125, 884-894	

1690	The role of rHuEpo in low-risk myelodysplastic syndrome patients. 2005 , 46, 823-31	2
1689	Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. 2005 , 11, 3604-8	322
1688	Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. 2005 , 23, 5728-38	122
1687	Bimodal Cell Populations Are Common in Chronic Lymphocytic Leukemia but Do Not Impact Overall Survival. 2005 , 123, 818-825	7
1686	The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. 2005 , 10 Suppl 1, 258-69	56
1685	Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS). 2005 , 2005, 167-73	22
1684	Acute megakaryoblastic leukemia with erythrophagocytosis and thrombosis in a dog. 2005 , 34, 52-6	17
1683	Classification of myeloid neoplasms: a comparative review. 2005 , 34, 189-212	44
1682	Recognition and Classification of Dysmyelopoiesis in the Dog: A Review. 2005 , 19, 147-154	21
1681	Management of anemia associated with myelodysplastic syndrome. 2005 , 42, S10-3	23
1680	Decitabine in myelodysplastic syndromes. 2005 , 42, S23-31	22
1679	Clinical implications of blast immunophenotypes in myelodysplastic syndromes. 2005 , 46, 1269-74	19
1678	Myelodysplastic syndrome. 2005 , 56, 1-16	96
1677	Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. 2005 , 11, 65-73	96
1676	Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning. 2005 , 11, 437-47	24
1675	Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. 2005 , 11, 619-26	12
1674	Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. 2005 , 11, 713-20	51
1673	Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. 2005 , 11, 764-72	61

1672	[Thalidomide: mechanisms of action and new insights in hematology]. 2005 , 26, 119-27	7
1671	[Iron overload in myelodysplastic syndromes. Role of iron chelators]. 2005 , 124, 654-5	
1670	Alternative treatments for myelodysplastic syndromes. 2005 , 42, S32-7	3
1669	Myelodysplastic syndromes--coping with ineffective hematopoiesis. 2005 , 352, 536-8	272
1668	Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. 2005 , 80, 681-98	39
1667	Myeloid Leukemia. 2005 ,	
1666	Cytogenetic and FISH techniques in myeloid malignancies. 2006 , 125, 13-26	2
1665	Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. 2006 , 355, 1456-65	1029
1664	The myelodysplastic syndromes: diagnosis and treatment. 2006 , 81, 104-30	145
1663	Atypical myeloproliferative disorders: diagnosis and management. 2006 , 81, 553-63	38
1662	Prognostic significance of monocytosis in patients with myeloproliferative disorders. 2006 , 47, 417-23	17
1661	Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes. 2006 , 47, 433-40	16
1660	Haemopoietic growth factors in the treatment of myelodysplastic syndrome. 2006 , 16, 1557-1568	0
1659	Myelodysplastic Syndrome with Deletion 5q Abnormality and Its Treatment. 2006 , 1, 28-33	
1658	Iron chelation therapy for myelodysplastic syndrome: if and when. 2006 , 81, 197-8	9
1657	Myelodysplastic/Myeloproliferative Disorder Overlap Syndrome: How Should it be Approached?. 2006 , 1, 95-100	1
1656	Decitabine: in myelodysplastic syndromes. 2006 , 66, 951-8	7
1655	Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. 2006 , 4, 11	7

1654	Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. 2006 , 19, 519-33		18
1653	Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. 2006 , 19, 571-93		36
1652	Myelodysplasia: when to treat and how. 2006 , 19, 293-300		8
1651	Immunomodulation in myelodysplastic syndromes. 2006 , 19, 757-67		4
1650	Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. 2006 , 12, 573-84		75
1649	Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. 2006 , 12, 749-57		24
1648	Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications. 2006 , 235, 177-90		17
1647	Telomeres and telomerase in cancer stem cells. 2006 , 42, 1197-203		82
1646	[Recent advances in the treatment of myelodysplastic syndromes]. 2006 , 27, 600-9		1
1645	Tratamento de suporte e quelaõ de ferro em pacientes com sãdromes mielodisplãicas. 2006 , 28, 204		
1644	The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome. 2006 , 21, 40-5		2
1643	Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. 2006 , 13 Suppl, 4-11		31
1642	Developmental therapeutics for myelodysplastic syndromes. 2006 , 4, 78-82		7
1641	Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes. 2006 , 13 Suppl, 12-6		2
1640	Alteraçõs cromossõmicas em sãdrome mielodisplãica. 2006 , 28, 182		5
1639	Real-time PCR as a tool for quantitative analysis of PI-PLC β gene expression in myelodysplastic syndrome. 2006 , 18, 267		2
1638	Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. <i>Blood</i> , 2006 , 108, 836-46	2.2	296
1637	Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. <i>Blood</i> , 2006 , 108, 337-45	2.2	165

1636	Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. <i>Blood</i> , 2006 , 108, 1037-44	2.2	125
1635	Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. <i>Blood</i> , 2006 , 108, 2173-81	2.2	168
1634	Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. <i>Blood</i> , 2006 , 108, 4170-7	2.2	108
1633	Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. 2006 , 4, 83-90		7
1632	Myelodysplastic syndromes. 43-57		1
1631	Myelodysplasia with isolated trisomy 15: a 15-year follow-up without specific therapy. 2006 , 331, 157-8		6
1630	Syndromes mylodysplasiques et leucmies secondaires. 2006 , 1, 1-14		
1629	The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights. 2006 , 11, 1-13		16
1628	Myelodysplastic Syndromes: Iron Overload Consequences and Current Chelating Therapies. 2006 , 4, 91-96		68
1627	[Diagnosis of and therapeutic strategy for myelodysplastic syndrome]. 2006 , 95, 538-43		
1626	Extensive myocardial infiltration by hemopoietic precursors in a patient with myelodysplastic syndrome. 2006 , 6, 4		7
1625	Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. 2006 , 132, 162-7		24
1624	High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. 2006 , 133, 513-9		83
1623	Platelet mass has prognostic value in patients with myelodysplastic syndromes. 2006 , 135, 198-200		20
1622	Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. 2006 , 135, 201-9		48
1621	Clinical implications of SOCS1 methylation in myelodysplastic syndrome. 2006 , 135, 317-23		29
1620	Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. 2006 , 20, 128-35		202
1619	Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. 2006 , 20, 230-8		87

1618	Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. 2006 , 20, 463-70	88
1617	Reply to Herens et al.. 2006 , 20, 522-523	2
1616	Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 2006 , 20, 549-55	100
1615	Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. 2006 , 20, 1943-9	125
1614	The fundamental role of epigenetics in hematopoietic malignancies. 2006 , 20, 1-13	174
1613	Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodysplastic syndromes. 2006 , 30, 178-82	12
1612	Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. 2006 , 30, 247-53	26
1611	Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. 2006 , 30, 385-8	15
1610	The 5q- syndrome and autoimmune phenomena: report of three cases. 2006 , 30, 507-10	5
1609	Prevalence of MDS subtypes in Shanghai, China: a comparison of the World Health Organization and French American British classifications. 2006 , 30, 769-75	23
1608	Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients. 2006 , 30, 971-7	22
1607	Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen. 2006 , 30, 935-42	7
1606	Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. 2006 , 30, 957-63	19
1605	Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. 2006 , 30, 1227-33	20
1604	Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. 2006 , 30, 813-22	43
1603	Gain of 1q in pediatric myelodysplastic syndromes. 2006 , 30, 1437-41	7
1602	Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia. 2006 , 30, 1043-7	7
1601	Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome. 2006 , 30, 1347-53	12

1600	The role of flow cytometric immunophenotyping in myelodysplastic syndromes. 2006 , 1089, 383-94	10
1599	Clinical relevance of cytogenetics in myelodysplastic syndromes. 2006 , 1089, 395-410	25
1598	Successful reduced-intensity hematopoietic stem cell transplantation in myelodysplastic syndrome with severe coronary artery disease. 2006 , 83, 156-8	1
1597	Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes. 2006 , 23, 37-49	12
1596	Characterization of the hemopoietic defect in early stages of the myelodysplastic syndromes. 2006 , 46, 98-112	2
1595	Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis. 2006 , 85, 502-13	31
1594	Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. 2006 , 85, 174-80	67
1593	Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. 2007 , 86, 133-7	28
1592	[Anemias]. 2006 , 118, 69-83; quiz 84	
1591	Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification. 2006 , 1, 9-15	
1590	Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?. 2006 , 1, 16-9	2
1589	New agents in myelodysplastic syndromes. 2006 , 1, 25-33	
1588	Arsenic trioxide as a treatment for myelodysplastic syndrome. 2006 , 1, 34-8	3
1587	Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. 2006 , 76, 23-32	155
1586	Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. 2006 , 76, 414-9	24
1585	A pharmacodynamic study of 5-azacytidine in the P39 cell line. 2006 , 34, 35-43	19
1584	Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10). 2006 , 165, 161-6	16
1583	Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia. 2006 , 165, 51-63	25

1582	Isochromosome 17q in MDS: a marker of a distinct entity. 2006 , 166, 189-90	15
1581	A rare case of acute myeloid leukemia evolving from a myelodysplastic syndrome with der(19)t(1;19). 2006 , 169, 181-3	5
1580	Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly. 2006 , 169, 69-72	16
1579	A novel isoderivative chromosome 20 in a patient with chronic myelomonocytic leukemia. 2006 , 170, 80-2	8
1578	Unusual complex hyperdiploid karyotypes in myelodysplastic syndromes. 2006 , 170, 129-32	4
1577	Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. 2006 , 171, 9-16	26
1576	Myelodysplastic syndrome associated with monosomy 7 in childhood: a retrospective study. 2006 , 171, 72-5	19
1575	Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. 2006 , 76, 494-501	17
1574	Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes. 2006 , 56, 191-9	4
1573	Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia. 2006 , 70, 63-70	17
1572	A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. 2006 , 207, 354-63	40
1571	FISH studies identify the i(20q-) anomaly as a der(20)del(20)(q11q13)idic(20)(p11). 2006 , 45, 536-9	15
1570	Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. 2006 , 106, 1099-109	89
1569	Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. 2006 , 106, 1794-803	1228
1568	Drug therapy for myelodysplastic syndrome: building evidence for action. 2006 , 106, 1650-2	2
1567	Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. 2006 , 106, 1744-50	56
1566	Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. 2006 , 106, 2087-94	57
1565	Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. 2006 , 107, 767-72	28

1564	Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. 2006 , 107, 1525-9	26
1563	Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. 2006 , 107, 2807-16	30
1562	Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?. 2006 , 24, 181-8	40
1561	Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients. 2006 , 81, 484-91	14
1560	A singular case of multiple myeloma and primary biliary cirrhosis strictly associated in pathogenesis and response to alkylating therapy. 2006 , 81, 557	1
1559	Idiopathic myelofibrosis associated with dermatomyositis. 2006 , 81, 559-60	4
1558	Development of secondary myelodysplastic syndrome in a patient with previous bladder carcinoma. 2006 , 81, 560	
1557	Implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis. 2006 , 81, 560-1	6
1556	Clinically significant pseudohyponatremia. 2006 , 81, 558-9	10
1555	Myelodysplasia with erythroid hypoplasia. 2006 , 81, 557-8	2
1554	Fluorescence in situ hybridization reveals closely correlated results in cytological and histological specimens of hematological neoplasias compared to conventional cytogenetics. 2006 , 73, 271-9	4
1553	Treatment of the 5q- syndrome. 2006 , 2006, 192-8	8
1552	Fluorescence In Situ Hybridization. 2006 , 189-202	1
1551	DNA micro-array analysis of myelodysplastic syndrome. 2006 , 47, 9-14	10
1550	Biological Basis of Novel Therapies for Myelodysplastic Syndrome. 2006 , 2, 199-209	
1549	Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. 2006 , 12, 5-10	104
1548	Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. 2006 , 24, 2480-9	151
1547	Telomeres and telomerase in stem cells during aging and disease. 2006 , 1, 84-103	32

1546	Advances in the management of low- to intermediate-risk myelodysplastic syndrome: Integrating the National Comprehensive Cancer Network guidelines. 2006 , 10, 197-208	2
1545	Diagnostics, prognostic and therapeutic exploitation of telomeres and telomerase in leukemias. 2006 , 7, 171-83	8
1544	Chronic Myelomonocytic Leukemia Evolving From Preexisting Myelodysplasia Shares Many Features With De Novo Disease. 2006 , 126, 789-797	35
1543	Is intravenous arsenic trioxide a useful therapy in myelodysplastic syndromes?. 2006 , 24, 2414-6	
1542	Myelodysplastic syndromes in patients younger than age 50. 2006 , 24, 5358-65	82
1541	Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease. 2006 , 24, e23-5	16
1540	Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. 2006 , 66, 6361-9	429
1539	Rapid progression of Myelodysplastic syndrome to acute myeloid leukemia on sequential azathioprine, IFN-beta and copolymer-1 in a patient with multiple sclerosis. 2006 , 116, 207-10	7
1538	Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group. 2006 , 060928002456003-???	
1537	Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. 2006 , 125, 884-94	34
1536	Advances in erythropoietic growth factor therapy for myelodysplastic syndromes. 2006 , 6, 1099-104	5
1535	Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. 2007 , 104, 1307-12	63
1534	Going from genes to proteins in myelodysplastic syndromes. 2007 , 104, 1109-10	1
1533	Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. 2007 , 127, 197-205	73
1532	The evolving role of lenalidomide in the treatment of hematologic malignancies. 2007 , 8, 497-509	44
1531	The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. 2007 , 67, 4287-94	75
1530	Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. 2007 , 2007, 392-7	59
1529	Management of RBC-transfusion dependence. 2007 , 2007, 398-404	12

1528	Modifying the epigenome as a therapeutic strategy in myelodysplasia. 2007 , 2007, 405-11	18
1527	Circulating adiponectin and leptin in relation to myelodysplastic syndrome: a case-control study. 2007 , 73, 26-32	30
1526	Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. 2007 , 48, 1150-60	51
1525	A pilot study of bendamustine in elderly patients with high-risk MDS and AML. 2007 , 48, 1161-6	11
1524	White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia. 2007 , 48, 1561-8	12
1523	The myelodysplastic syndromes. 2007 , 7, 369-77	17
1522	Modern Hematology. 2007 ,	15
1521	The role of azacitidine in the treatment of myelodysplastic syndromes. 2007 , 16, 1967-75	17
1520	Analysis of FLT3 gene mutations in de novo myelodysplastic syndromes. FLT3 internal tandem duplication detected in a case of refractory anemia. 2007 , 48, 2437-40	2
1519	Acute myeloid leukemia and myelodysplastic syndromes in older patients. 2007 , 25, 1908-15	197
1518	RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. 2007 , 67, 1997-2005	61
1517	Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. 2007 , 12, 1264-73	57
1516	Living Donor Transplantation. 2007 ,	2
1515	Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival. 2007 , 117, 221-5	3
1514	Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches. 2007 , 7, 541-58	24
1513	Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. 2007 , 25, 3503-10	810
1512	Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. 2007 , 13, 7107-12	43
1511	Defective platelet aggregation in myelodysplastic syndromes. 2007 , 118, 117-22	21

1510 [Guideline for the care of hematologic diseases based on EBM]. **2007**, 96, 475-82

1509 Chronic myelomonocytic leukemia in the light of the WHO proposals. **2007**, 92, 974-7

62

1508 Myelodysplastic Syndromes. 473-489

1507 Blood and Bone Marrow: Myeloid Leukaemias and Related Neoplasms. **2007**,

1506 A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. *Blood*, **2007**, 109, 4158-63

2.2 93

1505 Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. *Blood*, **2007**, 110, 1379-87

2.2 125

1504 Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. *Blood*, **2007**, 110, 3365-73

2.2 174

1503 New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. *Blood*, **2007**, 110, 4385-95

2.2 585

1502 Evolving classifications of the myelodysplastic syndromes. **2007**, 14, 98-105

13

1501 The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. **2007**, 14, 123-9

33

1500 A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. **2007**, 92, 744-52

122

1499 Anomalies chromosomiques et gñiques dans les hñopathies malignes. **2007**, 2, 1-13

1498 Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. **2007**, 55, 37-48

71

1497 Strategies for achieving transfusion independence in myelodysplastic syndromes. **2007**, 11, 151-8

6

1496 Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. **2007**, 13, 345-54

40

1495 Sympathectomy protects denervated skin from graft-versus-host disease. **2007**, 13, 369-70

1494 Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. **2007**, 13, 454-62

100

1493 Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. **2007**, 13, 655-64

121

1492	Clinical features and prognosis of patients with myelodysplastic syndromes. 2007 , 33, S15-S18	4
1491	Immunosuppressive treatment strategies in low-risk MDS. 2007 , 33, S11-S14	1
1490	Current treatment strategies in low-risk myelodysplastic syndromes. 2007 , 33, S19-S24	2
1489	A comprehensive approach to the diagnosis of MDS after triage by morphology towards cytogenetics and other techniques. 2007 , 33, S31-S41	1
1488	Treatment of patients with high-risk myelodysplastic syndromes. 2007 , 33, S64-S68	3
1487	Molecular Targets in Myelodysplastic Syndromes. 2007 , 33, S42-S46	
1486	Cytogenetic subtypes of MDS [Molecular background, prognostic relevance and therapeutic consequences. 2007 , 33, S25-S30	
1485	[Myelodysplastic syndromes in adults]. 2007 , 36, 481-91	2
1484	Hematopoietic growth factors in the treatment of acquired bone marrow failure states. 2007 , 44, 138-47	40
1483	Autologous stem cell transplantation in myelodysplastic syndromes. 2007 , 44, 274-7	9
1482	Clinicopathologic analysis of acute myeloid leukemia in a single institution: biphenotypic acute myeloid leukemia may not be an aggressive subtype. 2007 , 70, 269-73	9
1481	The role of decitabine in the treatment of myelodysplastic syndromes. 2007 , 8, 65-73	24
1480	The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey. 2007 , 48, 1372-8	10
1479	Acute Myelogenous Leukemia. 2007 ,	
1478	Differentiation and hematopoietic-support of clonal cells in myelodysplastic syndromes. 2007 , 48, 1353-71	8
1477	Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications. 2007 , 48, 1900-9	19
1476	The use of hypomethylating agents in the treatment of hematologic malignancies. 2007 , 48, 1676-95	34
1475	Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes. 2007 , 48, 2375-80	3

1474	Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. 2007 , 25, 4246-54	320
1473	Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes. 2007 , 1, 353-356	6
1472	Myelodysplastic Syndromes: Impact of Recently Analyzed Variables for Modifying Current Classification Methods. 2007 , 1, 172-182	2
1471	FISH panels for hematologic malignancies. 2007 , 118, 284-96	30
1470	Risk assessment in haematopoietic stem cell transplantation: disease and disease stage. 2007 , 20, 125-54	22
1469	Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. 2007 , 92, 1119-22	35
1468	Azacitidine-induced Hepatotoxicity in a Patient with Myelodysplastic Syndrome. 2007 , 42, 176	
1467	The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia. 2007 , 92, 723-7	13
1466	. 2007 ,	36
1465	Qualitative changes of hematopoiesis. 95-119	0
1464	Platelet disorders in the elderly. 420-433	
1463	Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. 2007 , 82, 867-72	46
1462	Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. 2007 , 46, 1119-28	40
1461	Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. 2007 , 109, 265-73	94
1460	Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. 2007 , 109, 713-7	106
1459	A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. 2007 , 109, 1125-32	27
1458	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. 2007 , 109, 1133-7	158
1457	Myelodysplastic syndromes: incidence and survival in the United States. 2007 , 109, 1536-42	415

1456	The incidence and impact of thrombocytopenia in myelodysplastic syndromes. 2007 , 109, 1705-14	179
1455	Therapy may unmask hypoplastic myelodysplastic syndrome that mimics aplastic anemia. 2007 , 110, 1520-6	15
1454	Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome. 2007 , 21, 49-59	14
1453	Allogeneic transplantation for myelodysplastic syndrome (MDS). 2007 , 21, 61-71	14
1452	Decitabine--bedside to bench. 2007 , 61, 140-52	134
1451	FLT3 mutation and AML/ETO in a case of Myelodysplastic syndrome in transformation corroborates the two hit model of leukemogenesis. 2007 , 31, 1015-8	7
1450	Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?. 2007 , 31, 1315-7	2
1449	Prognostic signature of ALL blasts at diagnosis: what can we really find?. 2007 , 31, 1317-9	2
1448	Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. 2007 , 31, 427-34	42
1447	Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). 2007 , 31, 791-7	7
1446	Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. 2007 , 31, 727-36	393
1445	Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome. 2007 , 31, 1343-9	12
1444	Increased apoptosis of circulating T cells in myelodysplastic syndromes. 2007 , 31, 1641-8	14
1443	Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. 2007 , 31, 1609-16	40
1442	Bone marrow mononuclear cells of MDS patients are characterized by in vitro proliferation and increased apoptosis independently of stromal interactions. 2007 , 31, 1659-67	5
1441	23 WPSS, a dynamic prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. 2007 , 31, S13-S14	1
1440	24 Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndrome. 2007 , 31, S14	
1439	Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. 2007 , 31 Suppl 3, S2-6	98

1438	Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. 2007 , 31 Suppl 3, S7-9	60
1437	Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. 2007 , 31 Suppl 3, S16-22	11
1436	Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. 2007 , 26, 2299-307	42
1435	Myelodysplastic syndromes: the complexity of stem-cell diseases. 2007 , 7, 118-29	271
1434	Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. 2007 , 40, 843-50	38
1433	Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. 2007 , 21, 480-8	17
1432	A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. 2007 , 21, 668-77	51
1431	Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. 2007 , 21, 678-86	39
1430	Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. 2007 , 21, 659-67	93
1429	Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms. 2007 , 21, 992-7	41
1428	Monosomy 7 in myeloid malignancies: parental origin and monitoring by real-time quantitative PCR. 2007 , 21, 1833-5	16
1427	Single nucleotide polymorphism arrays complement metaphase cytogenetics in detection of new chromosomal lesions in MDS. 2007 , 21, 2058-61	31
1426	Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. 2007 , 21, 1648-57	51
1425	A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). 2007 , 21, 1945-51	28
1424	CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. 2007 , 21, 1937-44	138
1423	Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. 2007 , 21, 2442-51	281
1422	Telomere and telomerase in stem cells. 2007 , 96, 1020-4	355
1421	A partial nucleated differential cell count of the bone marrow aspirate that is independent of peripheral blood dilution. 2008 , 30, 473-9	3

1420	World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. 2007 , 137, 193-205	72
1419	Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. 2007 , 137, 125-32	63
1418	Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes. 2007 , 138, 399-400	10
1417	Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. 2007 , 138, 555-7	5
1416	Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. 2007 , 138, 587-93	76
1415	Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. 2007 , 139, 265-8	49
1414	Familial myelodysplasia and acute myeloid leukaemia--a review. 2008 , 140, 123-32	139
1413	Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004. 2007 , 17, 151-60	3
1412	Sweet's syndrome associated with skin methicillin-resistant Staphylococcus epidermidis infection. 2007 , 34, 258-61	4
1411	Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer. 2007 , 27, 434-46	4
1410	Cytogenetic bichlonality in a child with hypocellular primary myelodysplastic syndrome. 2007 , 178, 70-2	5
1409	Constitutional trisomy 8 mosaicism in primary myelofibrosis: relevance to clinical practice and warning for trisomy 8 studies. 2007 , 179, 79-81	13
1408	Enhanced growth of myelodysplastic colonies in hypoxic conditions. 2007 , 35, 21-31	25
1407	High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. 2007 , 35, 240-51	28
1406	Recent advances in myelodysplastic syndromes. 2007 , 35, 137-43	40
1405	Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. 2007 , 35, 1728-38	47
1404	Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. 2007 , 35, 1668-76	35
1403	Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. 2007 , 35, 1739-46	97

1402	The use of scoring systems in patients with haematological malignancy. 2007 , 95, 47-51	1
1401	Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group. 2007 , 78, 89-90	1
1400	An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia. 2007 , 78, 41-7	2
1399	Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes. 2008 , 80, 107-14	4
1398	Immunomodulatory therapy for myelodysplastic syndromes. 2007 , 86, 301-5	9
1397	Evolving new treatment for myelodysplastic syndromes. 2007 , 86, 297-300	0
1396	Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. 2007 , 86, 306-14	14
1395	A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response. 2007 , 86, 150-7	18
1394	The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome. 2007 , 85, 446-55	6
1393	Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes. 2007 , 86, 185-9	15
1392	A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. 2007 , 18, 1199-208	23
1391	Differentiating megakaryocytes in myelodysplastic syndromes succumb to mitochondrial derangement without caspase activation. 2007 , 12, 1101-8	7
1390	Current treatment options: impact of cytogenetics on the course of myelodysplasia. 2007 , 8, 117-28	24
1389	Mixed myeloproliferative and myelodysplastic disorders. 2007 , 2, 9-12	3
1388	Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome?. 2008 , 19, 371-8	14
1387	Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. 2008 , 87, 345-52	64
1386	Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. 2008 , 87, 527-36	103
1385	Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. 2008 , 87, 537-44	32

1384	Cytogenetic features in myelodysplastic syndromes. 2008 , 87, 515-26	148
1383	Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. 2008 , 87, 691-9	70
1382	FISH in der Diagnostik hämatologischer Neoplasien. 2008 , 20, 367-373	
1381	Lenalidomide in myelodysplastic syndromes: where do we go from here?. 2008 , 3, 5-9	
1380	Prognosis in myelodysplastic syndromes: are the new classifications useful?. 2008 , 3, 19-22	
1379	Immunosuppressive therapy for myelodysplastic syndromes: refining the indications. 2008 , 3, 23-8	6
1378	Diagnosis and management of chronic myelomonocytic leukemia. 2008 , 3, 31-6	4
1377	Myelodysplastic syndrome: an update on diagnosis and therapy. 2008 , 10, 372-8	5
1376	Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. 2008 , 88, 24-29	87
1375	Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. 2008 , 13, 1148-61	35
1374	[Individualized management and therapy of myelodysplastic syndromes]. 2008 , 120, 523-37	5
1373	The deleterious effects of iron overload in patients with myelodysplastic syndromes. 2008 , 22 Suppl 2, S29-34	22
1372	Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7. 2008 , 50, 670-2	5
1371	Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. 2008 , 112, 1089-95	57
1370	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. 2008 , 113, 1933-52	74
1369	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. 2008 , 113, 1351-61	386
1368	Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. 2008 , 113, 3331-40	91
1367	Diagnostic flow cytometry for low-grade myelodysplastic syndromes. 2008 , 26, 193-8	23

1366	Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. 2008 , 83, 611-3	65
1365	Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era. 2008 , 83, 708-13	24
1364	International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. 2008 , 83, 765-70	78
1363	Antithymocyte globulin therapy for steroid-resistant acute graft versus host disease. 2008 , 83, 824-5	4
1362	A case report of concomitant paroxysmal nocturnal hemoglobinuria and sickle cell disease. 2008 , 83, 823	1
1361	RAD51 and XRCC3 polymorphism frequency and risk of myelodysplastic syndromes. 2008 , 83, 822-3	8
1360	Hemolytic anemia following intravenous immunoglobulin administration. 2008 , 83, 825	9
1359	Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation. 2008 , 83, 825-7	7
1358	Prognostic relevance of anemia in myelodysplastic syndromes. 2008 , 83, 761-2	3
1357	Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. 2008 , 32, 33-7	27
1356	Flow cytometry in myelodysplastic syndromes: report from a working conference. 2008 , 32, 5-17	77
1355	Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. 2008 , 32, 251-4	11
1354	Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification. 2008 , 32, 514-6	26
1353	On flow cytometry in myelodysplastic syndromes, with caveats. 2008 , 32, 209-10	4
1352	Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). 2008 , 32, 587-91	104
1351	Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. 2008 , 32, 553-8	35
1350	Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. 2008 , 32, 691-8	70
1349	Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. 2008 , 32, 1439-47	16

1348	Pregnancy in patients with myelodysplastic syndromes (MDS). 2008 , 32, 1605-7	4
1347	Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. 2008 , 32, 1541-5	27
1346	Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia. 2008 , 32, 1374-81	2
1345	Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. 2008 , 32, 1338-53	44
1344	International Working Group on MDS cytogenetics: October 2007 meeting report. 2008 , 32, 1329-32	10
1343	Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. 2008 , 32, 1715-23	18
1342	Kala-azar: a possible misdiagnosis of myelodysplastic syndrome in endemic areas. 2008 , 32, 1786-9	1
1341	Cytogenetic abnormalities in Tunisian de novo myelodysplastic syndrome: a comparison with other populations. 2008 , 32, 1824-9	6
1340	Supportive care, growth factors, and new therapies in myelodysplastic syndromes. 2008 , 22, 75-91	18
1339	Cutaneous granulocytic sarcoma in myelodysplastic syndrome. 2008 , 35, 876-9	10
1338	The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. 2008 , 22, 1308-19	143
1337	Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum. 2008 , 22, 1864-73	20
1336	Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan. 2008 , 22, 1874-81	17
1335	Low frequency of the glutathione-S-transferase T1-null genotype in patients with primary myelodysplastic syndrome and 5q deletion. 2008 , 22, 1643-6	5
1334	The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. 2008 , 22, 1175-83	96
1333	Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. 2008 , 21, 1394-402	38
1332	Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML. 2008 , 42, 659-66	9
1331	Abstracts of the XXIst International Symposium on Technological Innovations in Laboratory Hematology. April 28-May 1, 2008. Sydney, Australia. 2008 , 30 Suppl 1, 1-147	3

1330	Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. 2008 , 41, 33-8	52
1329	Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. 2008 , 22, 258-64	53
1328	Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. 2008 , 22, 313-22	78
1327	Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes. 2008 , 22, 530-7	41
1326	A prognostic score for patients with lower risk myelodysplastic syndrome. 2008 , 22, 538-43	244
1325	Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. 2008 , 22, 544-50	43
1324	Genetics of therapy-related myelodysplasia and acute myeloid leukemia. 2008 , 22, 240-8	180
1323	Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome. 2008 , 30, 390-9	13
1322	Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients. 2008 , 22, 543-8	30
1321	Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia. 2008 , 38, 824-8	3
1320	The role of lenalidomide in the management of myelodysplasia with del 5q. 2008 , 140, 267-78	24
1319	Platelet count is an IPSS-independent risk factor predicting survival in refractory anaemia with ringed sideroblasts. 2008 , 140, 722-5	7
1318	Bone marrow trephine morphology and immunohistochemical findings in chronic myelomonocytic leukaemia. 2008 , 141, 771-81	20
1317	Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. 2008 , 142, 379-93	66
1316	Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. 2008 , 142, 695-708	64
1315	Recent advances in the understanding of inherited sideroblastic anaemia. 2008 , 143, 27-38	59
1314	Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. 2008 , 38, 143-9	45
1313	Revealing the pathogenesis of the 5q- syndrome. 2008 , 38, 539-40	

1312	Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. 2008 , 38, 945-52	40
1311	Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia. 2008 , 58, 353-60	23
1310	Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. 2008 , 76, 1417-25	27
1309	FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia. 2008 , 183, 89-93	18
1308	Isoderivative chromosome 20 in bone marrow: three new cases. 2008 , 184, 72-3	6
1307	Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. 2008 , 187, 101-11	13
1306	Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. 2008 , 80, 197-200	56
1305	Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 2008 , 80, 216-26	35
1304	Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. 2008 , 81, 364-73	37
1303	[Myelodysplastic syndromes: therapeutic advances and promising future]. 2008 , 131, 500-2	1
1302	Role of epigenetic therapy in myelodysplastic syndrome. 2008 , 1, 161-74	
1301	Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. 2008 , 93, 1385-8	101
1300	World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. 2008 , 45, 3-7	13
1299	Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?. 2008 , 21, 67-77	9
1298	Fluorescence In Situ Hybridization (FISH) and Conventional Cytogenetics for Hematology and Oncology Diagnosis. 2008 , 303-364	
1297	Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. 2008 , 120, 70-4	87
1296	Targeted Cancer Therapy. 2008 ,	6
1295	[Evolution of transfusion requirements in hematology]. 2008 , 15, 247-53	

1294	Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. 2008 , 44, 1744-53	37
1293	A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. 2008 , 14, 28-35	48
1292	Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. 2008 , 14, 458-68	56
1291	Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. 2008 , 14, 672-84	136
1290	Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. 2008 , 14, 799-806	20
1289	Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). 2008 , 14, 1217-25	109
1288	The leukemias. 2008 , 20, 597-608	12
1287	Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. 2008 , 45, 14-22	39
1286	Allogeneic stem cell transplantation for myelodysplastic syndrome. 2008 , 45, 49-59	25
1285	Whole genome scanning as a cytogenetic tool in hematologic malignancies. <i>Blood</i> , 2008 , 112, 965-74	2.2 116
1284	Síndromes mielodisplásicos. 2008 , 10, 1402-1408	
1283	Active Treatment Strategies Improving Outcomes in Patients with Myelodysplastic Syndromes with the Deletion 5q Abnormality. 2008 , 2, 28-33	3
1282	Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy. 2008 , 2, 205-211	58
1281	Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. 2008 , 26, 5943-9	92
1280	What Is WHO Myelodysplastic Syndromes Classification. 2008 , 2, 20-27	1
1279	The Epidemiology of Myelodysplastic Syndromes. 2008 , 2, 34-38	6
1278	Myelodysplastic syndromes. <i>Blood</i> , 2008 , 111, 4841-51	2.2 292
1277	Current treatment options and strategies for myelodysplastic syndromes. 2008 , 9, 1667-78	3

1276	Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. 2008 , 49, 2141-7	64
1275	Treatment strategies in myelodysplastic syndromes. 2008 , 26, 208-16	9
1274	Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment. 2008 , 49, 346-9	7
1273	Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. 2008 , 49, 1963-75	30
1272	Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. 2008 , 26, 3607-13	225
1271	Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. 2008 , 100, 1542-51	209
1270	Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. 2008 , 19, 970-6	30
1269	In Reply. 2008 , 26, 1181-1182	3
1268	Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance. 2008 , 129, 478-85	24
1267	Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes. 2008 , 120, 104-7	15
1266	Leukemic cluster growth in culture is an independent risk factor for acute myeloid leukemia and short survival in patients with myelodysplastic syndrome. 2008 , 119, 226-35	4
1265	Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. 2008 , 166-75	68
1264	Treatment options in myelodysplastic syndromes: a new frontier. 2008 , 20, 291-6	3
1263	Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany. 2008 , 31, 477-84	2
1262	Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. 2008 , 49, 690-5	92
1261	Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. 2008 , 14, 509-14	19
1260	Clinician's Manual on Myelodysplastic Syndromes. 2008 ,	
1259	Solving the mystery of myelodysplasia. 2008 , 5, e40	3

1258	An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. 2008 , 5, e35		132
1257	Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. 2008 , 26, 2505-11		199
1256	Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. 2008 , 93, 1712-7		220
1255	Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. 2008 , 26, 577-84		173
1254	High expression of ERCC1, FLT1, NME4 and PCNA associated with poor prognosis and advanced stages in myelodysplastic syndrome. 2008 , 49, 1297-305		14
1253	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. 2008 , 93, 1001-8		27
1252	Iron overload in myelodysplastic syndromes. 2008 , 49, 427-38		30
1251	Granulocyte colony-stimulating factor and interleukin-6 production by myelodysplastic syndrome blasts. 2008 , 49, 589-91		3
1250	Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems. 2008 , 49, 1292-6		8
1249	Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?. 2008 , 49, 1225-7		2
1248	Phase II study of doxercaliferol for the treatment of myelodysplastic syndrome. 2008 , 49, 57-61		22
1247	[Myelodysplastic syndromes: clinically relevant aspects in diagnosis, prognosis and prediction]. 2008 , 133, 2086-90		1
1246	High prevalence of human T-lymphotropic virus type I carriers among patients with myelodysplastic syndrome refractory anemia with excess of blasts (RAEB), RAEB in transformation and acute promyelocytic leukemia. 2008 , 49, 315-21		3
1245	Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. 2008 , 93, 381-9		29
1244	Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. <i>Blood</i> , 2008 , 111, 86-93	2.2	351
1243	Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. <i>Blood</i> , 2008 , 111, 1534-42	2.2	281
1242	Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. <i>Blood</i> , 2008 , 111, 574-82	2.2	243
1241	Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. <i>Blood</i> , 2008 , 111, 1067-77	2.2	174

1240	High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. <i>Blood</i> , 2008 , 112, 3412-24	2.2	97
1239	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Blood</i> , 2008 , 112, 895-902	2.2	165
1238	Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. <i>Blood</i> , 2008 , 112, 2681-6	2.2	97
1237	Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. <i>Blood</i> , 2008 , 112, 3434-43	2.2	140
1236	Cutaneous leukocytoclastic vasculitis and myelodysplastic syndrome with little or no evidence of associated autoimmune disorders-a case report and a brief review of the literature. 2008 , 336, 368-71		15
1235	[Diagnosis and treatment of myelodysplastic syndrome]. 2008 , 97, 627-32		
1234	Impact of age and comorbidity in myelodysplastic syndromes. 2008 , 6, 927-34		26
1233	The role of flow cytometry in myelodysplastic syndromes. 2008 , 6, 935-41		10
1232	Hémochromatose post-transfusionnelle. 2008 , 3, 1-10		0
1231	Changing the treatment paradigm in myelodysplastic syndromes. 2008 , 15 Suppl, 14-28		15
1230	Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes. 2008 , 15 Suppl, 29-39		13
1229	Myelodysplastic syndromes: diagnosis and staging. 2008 , 15 Suppl, 4-13		38
1228	Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. 2008 , 15, 88-94		26
1227	Erythropoietin-stimulating agents in oncology. 2008 , 14, 75-84		3
1226	Behçet disease associated with myelodysplastic syndrome. 2008 , 14, 169-74		33
1225	Prognostic analysis of refractory anaemia in adult myelodysplastic syndromes. 2008 , 121, 1787-1791		1
1224	Karyotypic analysis of bone marrow cells in pyodermic lesions associated with myelodysplastic syndrome. 2008 , 144, 643-8		4
1223	Myelodysplastic Syndromes. 2008 , 129-154		

1222	The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines. 2008 , 6, 942-953	35
1221	Deferasirox for managing iron overload in patients with myelodysplastic syndrome. 2008 ,	
1220	Managing myelodysplastic symptoms in elderly patients. 2009 , 4, 413-23	28
1219	Therapeutic decision making in BMT/SCT for myelodysplasia. 85-98	
1218	The role of azacitidine in the management of myelodysplastic syndromes (MDS). 2009 , Volume 1, 119-130	4
1217	Differential gene expression of bone marrow CD34+ cells in early and advanced myelodysplastic syndrome. 2009 , 56, 335-42	5
1216	Azacitidine: A Review of its Use in the Management of Myelodysplastic Syndromes. 2009 , 1, CMT.S1163	
1215	Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival. 2009 , 94, 1453-5	17
1214	Comparison of I-FISH and G-banding for the detection of chromosomal abnormalities during the evolution of myelodysplastic syndrome. 2009 , 42, 1110-2	18
1213	Mielodisplasia en Pacientes Pediátricos: Evaluación de Clasificaciones Actuales. 2009 , 80,	
1212	Defective ribosome biogenesis in myelodysplastic syndromes. 2009 , 94, 1336-8	2
1211	Management of Multiple Myeloma and Myelodysplastic Syndrome: Focus on Lenalidomide. 2009 , 1, CMT.S2295	
1210	[Clarification of possible anemia]. 2009 , 98, 1453-5	0
1209	Immunotherapy: Can we include vaccines with stem-cell transplantation?. 2009 , 6, 503-5	12
1208	Myelodysplastic syndromes. 2009 , 132, 290-305	44
1207	Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 2009 , 106, 16811-6	88
1206	A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. 2009 , 106, 12974-9	167
1205	Acute Myeloid Leukaemia, Mixed Phenotype Acute Leukaemia, The Myelodysplastic Syndromes and Histiocytic Neoplasms. 166-238	

1204	Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. 2009 , 2, 69-80	34
1203	Diagnostic challenges in the myelodysplastic syndromes: the current and future role of genetic and immunophenotypic studies. 2009 , 3, 275-91	
1202	Bone Marrow. 2009 , 1536-1593	
1201	New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. 2009 , 27, 5219-26	99
1200	Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 2009 , 27, 782-90	52
1199	The myelodysplastic syndromes. 2009 , 71-79	
1198	Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. 2009 , 15, 5002-7	87
1197	The changing classification of myelodysplastic syndromes: what's in a name?. 2009 , 645-55	14
1196	Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?. 2009 , 664-72	23
1195	Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. 2009 , 94, 496-506	50
1194	Optimal sequencing of treatments for patients with myelodysplastic syndromes. 2009 , 16, 77-83	9
1193	Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. 2009 , 8, 883-9	24
1192	Myelodysplastic syndromes: classification and prognostic scoring systems and their applicability in Indian scenario-experience from a tertiary care center. 2009 , 14, 145-9	6
1191	High-dose daunorubicin in older patients with acute myeloid leukemia. 2009 , 361, 1235-48	622
1190	Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. 2009 , 2, 121-7	12
1189	Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia. 2009 , 94, 1338-40	8
1188	Hematology: Azacitidine improves survival in myelodysplastic syndromes. 2009 , 6, 502-3	3
1187	Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. 2009 , 94, 1124-34	172

1186	Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. 2009 , 69, 7518-23	29
1185	Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. 2009 , 27, 754-62	176
1184	Romiplostim: a novel thrombopoiesis-stimulating agent. 2009 , 66, 817-24	14
1183	Myelodysplastic disorders. 2009 , 37, 186-189	
1182	Trisomy 8 may not be related to the pathogenesis of myelodysplastic syndromes: disappearance of trisomy 8 in a patient with refractory anaemia without haematological improvement. 1998 , 60, 260-1	9
1181	Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas. 1999 , 62, 184-90	19
1180	The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. 2009 , 83, 328-33	25
1179	Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. 2009 , 83, 477-82	50
1178	Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia. 2009 , 83, 550-8	4
1177	Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. 2009 , 37, 947-55	58
1176	Accelerated cellular senescence in myelodysplastic syndrome. 2009 , 37, 1310-7	14
1175	Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS. 2009 , 193, 78-85	19
1174	Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. 2010 , 28, 40-8	24
1173	Experimental and clinical characteristics in myelodysplastic syndrome patients with or without HLA-DR15 allele. 2010 , 28, 98-103	5
1172	An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. 2009 , 115, 706-15	48
1171	The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes. 2009 , 115, 4524-32	17
1170	The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?. 2009 , 115, 5202-9	36
1169	Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. 2009 , 76, 27-36	56

1168	Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination. 2009 , 76, 18-26	40
1167	Telomere shortening and chromosomal instability in myelodysplastic syndromes. 2010 , 49, 260-9	50
1166	A scoring system to quantify late effects in children after treatment for medulloblastoma/ependymoma and its correlation with quality of life and neurocognitive functioning. 2009 , 25, 173-81	30
1165	Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States. 2009 , 20, 1369-76	10
1164	Unbalanced jumping translocation involving 3q in myeloproliferative disease. 2009 , 26, 251-5	4
1163	Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality. 2009 , 90, 353-360	14
1162	Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD. 2009 , 90, 361-369	11
1161	Immunosuppressive treatment in patient with pure red cell aplasia associated with chronic myelomonocytic leukemia: harm or benefit?. 2009 , 90, 597-600	4
1160	Management of myelodysplastic syndromes in the geriatric patient. 2009 , 4, 3-9	6
1159	Myelodysplastic syndrome: An update on diagnosis and therapy. 2009 , 4, 10-6	1
1158	Myelodysplastische Syndrome (MDS). 2009 , 2, 59-66	
1157	Analysis of WHO-based Prognostic Scoring System (WPSS) of myelody-splastic syndrome and its comparison with international prognostic scoring system (IPSS) in 100 Chinese patients. 2009 , 21, 50-55	2
1156	Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS). 2009 , 2, 13-17	
1155	Paroxysmal nocturnal hemoglobinuria clone in a case of myelodysplastic syndrome rapidly progressing to acute leukemia. 2009 , 25, 33-5	
1154	Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. 2009 , 2, 2-8	33
1153	A limited number of 5-azacitidine cycles can be effective treatment in MDS. 2009 , 88, 213-9	27
1152	No telomere shortening in marrow stroma from patients with MDS. 2009 , 88, 623-8	9
1151	Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes. 2009 , 88, 607-11	7

1150	Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. 2009 , 88, 1207-13	39
1149	Avancès cytoghétiques dans les syndromes myfodysplasiques. 2009 , 2009, 59-66	
1148	11 Real-time prognostic evaluation in MDS. 2009 , 33, S8-S9	
1147	12 Updated cytogenetic risk features in MDS [present state. 2009 , 33, S9-S10	6
1146	17 Myelodysplastic syndromes with unilineage cytopenia (neutropenia/thrombocytopenia). 2009 , 33, S11-S14	
1145	Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes. 2009 , 33 Suppl 2, S7-11	40
1144	Azacitidine in lower-risk myelodysplastic syndromes. 2009 , 33 Suppl 2, S22-6	10
1143	Van-den Berghe's 5q- syndrome in 2008. 2009 , 144, 157-68	23
1142	Totipotent stem cells bearing del(20q) maintain multipotential differentiation in Shwachman Diamond syndrome. 2009 , 144, 116-9	18
1141	Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes. 2009 , 144, 342-9	15
1140	Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?. 2009 , 144, 809-17	29
1139	The route to development of myelodysplastic syndrome/acute myeloid leukaemia in Shwachman-Diamond syndrome: the role of ageing, karyotype instability, and acquired chromosome anomalies. 2009 , 145, 190-7	54
1138	Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. 2009 , 145, 569-80	94
1137	Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. 2009 , 145, 788-800	460
1136	Successful routine cytogenetic analysis from trephine biopsy specimens following failure to aspirate bone marrow. 2009 , 146, 573	6
1135	Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. 2009 , 146, 627-36	50
1134	Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF. 2010 , 149, 844-54	25
1133	Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. 2009 , 39, 406-11	27

1132	Comorbidity, iron overload and HFE variants: a new prognostic complex in MDS?. 2009 , 39, 1112-3	1
1131	Myelodysplastic syndromes: biology and treatment. 2009 , 265, 307-28	44
1130	Improving the prognostic evaluation of patients with lower risk myelodysplastic syndromes. 2009 , 23, 182-4; author reply 185	8
1129	Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria. 2009 , 23, 886-91	38
1128	Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. 2009 , 23, 1288-96	52
1127	RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. 2009 , 23, 1426-31	123
1126	Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. 2009 , 23, 1252-6	73
1125	Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. 2009 , 23, 1605-13	77
1124	Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice. 2009 , 43, 351-6	21
1123	ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. 2009 , 28, 1099-109	53
1122	Traitement des syndromes myélodysplasiques. 2009 , 2009, 77-85	0
1121	CD34, RAB20, PU.1 and GFI1 mRNA expression in myelodysplastic syndrome. 2009 , 31, 344-51	15
1120	Do peripheral blasts count in myelodysplastic syndromes?. 2009 , 33, 209-11	4
1119	Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. 2009 , 33, 391-4	3
1118	Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes. 2009 , 33, 326-31	13
1117	John Auer and Auer rods; controversies revisited. 2009 , 33, 614-6	12
1116	Polymorphisms of detoxification and DNA repair enzymes in myelodysplastic syndromes. 2009 , 33, 1068-71	22
1115	Myelodysplasia paranoia: iron as the new radon. 2009 , 33, 1158-63	30

1114	WPSS versus simplified myelodysplastic syndrome risk score: Which is the best tool for prediction of survival in myelodysplastic patients?. 2009 , 33, e93-4	5
1113	Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients. 2009 , 33, 1194-8	19
1112	Iron overload, cardiac iron loading and function in myelodysplastic syndrome. 2009 , 33, 743-4	2
1111	Impact on survival of different treatments for myelodysplastic syndromes (MDS). 2009 , 33, 1024-8	36
1110	Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. 2009 , 33, 1594-8	68
1109	Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows. 2009 , 33, 1313-8	35
1108	Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias. 2009 , 33, 1636-42	0
1107	Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes. 2009 , 33, 1183-8	8
1106	Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. 2009 , 33, 1469-74	29
1105	Inflammatory myofibroblastic tumor of the bone marrow. 2009 , 33, e224-7	
1104	Mutation in TET2 in myeloid cancers. 2009 , 360, 2289-301	1376
1103	59-year-old man with MDS. 2009 , 15, 1001-2	
1102	Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. 2009 , 15, 30-8	111
1101	IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. 2009 , 15, 205-13	18
1100	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. 2009 , 15, 137-72	59
1099	Hematopoiesis-related microRNA expression in myelodysplastic syndromes. 2009 , 50, 1854-9	74
1098	Myelodysplastic syndromes. 2009 , 361, 1872-85	527
1097	Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. 2009 , 69, 2501-18	20

1096	Progress in myelodysplastic syndromes. 2009 , 9 Suppl 3, S286-92			2
1095	Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes. 2009 , 9 Suppl 3, S305-11			12
1094	Telomeres and Telomerase in Cancer. 2009 ,			9
1093	Encyclopedia of Cancer. 2008 , 1764-1764			
1092	Prognostic molecular markers in myelodysplastic syndromes. 2009 , 2, 563-75			
1091	Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by French-American-British and World Health Organisation classifications. 2009 , 50, 841-3			0
1090	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. <i>Blood</i> , 2009 , 113, 2895-901	2.2		905
1089	Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. 2009 , 94, 1066-74			105
1088	Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. 2009 , 50, 1461-7			19
1087	Iron chelation therapy for patients with myelodysplastic syndrome. 2009 , 33, 339-45			1
1086	Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. 2009 , 28, 2205-18			47
1085	Clinical activity of laromustine (Onregin®) in hematologic malignancies. 2009 , 2, 481-8			1
1084	Update on genetic and molecular markers associated with myelodysplastic syndromes. 2009 , 50, 341-8			6
1083	Thrombocytopenia in myelodysplastic syndromes and myelofibrosis. 2009 , 46, S37-43			7
1082	Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. 2009 , 46, 371-7			68
1081	Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. 2009 , 10, 223-32			1961
1080	The myelodysplastic syndromes. 2009 , 23, 675-91			20
1079	Hypocellular myelodysplasia. 2009 , 23, 347-60			21

1078	The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. 2009 , 94, 729-32		75
1077	Treatment of MDS: something old, something new, something borrowed. 2009 , 656-63		4
1076	Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. <i>Blood</i> , 2009 , 113, 1432-43	2.2	87
1075	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. <i>Blood</i> , 2009 , 113, 3947-52	2.2	133
1074	How I treat patients with myelodysplastic syndromes. <i>Blood</i> , 2009 , 113, 6296-303	2.2	68
1073	The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. <i>Blood</i> , 2009 , 113, 4171-8	2.2	76
1072	Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. <i>Blood</i> , 2009 , 114, 1063-72	2.2	125
1071	Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. <i>Blood</i> , 2009 , 113, 6533-40	2.2	51
1070	A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. <i>Blood</i> , 2009 , 113, 6541-8	2.2	242
1069	Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). <i>Blood</i> , 2009 , 114, 2393-400	2.2	150
1068	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). <i>Blood</i> , 2009 , 114, 3285-91	2.2	231
1067	Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment. <i>Blood</i> , 2009 , 114, 2575-80	2.2	10
1066	Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. <i>Blood</i> , 2009 , 114, 4847-58	2.2	61
1065	Predictive factors of response and survival following chemotherapy treatment in acute myeloid leukemia progression from myelodysplastic syndrome. 2009 , 48, 1629-33		4
1064	Enhancing Survival Outcomes in the Management of Patients with Higher-Risk Myelodysplastic Syndromes. 2009 , 16, 2-10		9
1063	IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. 2010 , 95, 1668-74		155
1062	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. 2010 , 95, 476-84		116
1061	Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions. 2010 , 22, 150-4		2

1060	Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. 2010 , 33, 185-99		46
1059	Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. 2010 , 95, 406-14		36
1058	Comparison of immunological abnormalities of lymphocytes in bone marrow in myelodysplastic syndrome (MDS) and aplastic anemia (AA). 2010 , 49, 1349-55		13
1057	7. Clinical Practice of Treating Bone-marrow Failure- Focusing on Myelodysplastic Syndrome.. 2010 , 99, 584-590		
1056	Iron overload in myelodysplastic syndromes: diagnosis and management. 2010 , 17 Suppl, 2-8		11
1055	Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. 2010 , 95, 1754-61		62
1054	International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. <i>Blood</i> , 2010 , 115, 496-9	2.2	92
1053	Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. <i>Blood</i> , 2010 , 115, 1985-92	2.2	87
1052	Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. <i>Blood</i> , 2010 , 115, 2586-91	2.2	114
1051	Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. <i>Blood</i> , 2010 , 115, 1850-7	2.2	145
1050	Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. <i>Blood</i> , 2010 , 116, 1124-31	2.2	150
1049	IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. <i>Blood</i> , 2010 , 116, 5486-96	2.2	155
1048	Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. <i>Blood</i> , 2010 , 116, 3923-32	2.2	190
1047	Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. <i>Blood</i> , 2010 , 116, 3163-70	2.2	118
1046	Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. <i>Blood</i> , 2010 , 115, 1779-84	2.2	75
1045	Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. 2010 , 95, 892-9		16
1044	Inositide signaling in the nucleus: from physiology to pathology. 2010 , 50, 2-11		16
1043	Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. 2010 , 89, 15-23		10

1042	Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. 2010 , 89, 147-54	25
1041	Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. 2010 , 89, 365-74	64
1040	Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study. 2010 , 89, 535-44	16
1039	Mean corpuscular volume predicts prognosis in MDS patients with abnormal karyotypes. 2010 , 89, 671-9	8
1038	Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. 2010 , 89, 681-9	23
1037	Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution. 2010 , 89, 545-51	19
1036	Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. 2010 , 89, 841-50	27
1035	Iron chelation therapy in myelodysplastic syndromes: evidence-based rationale and comparison of guidelines. 2010 , 3, 11-15	
1034	Jumping translocation in acute monocytic leukemia (M5b) with alternative breakpoint sites in the long arm of donor chromosome 3. 2010 , 27, 667-72	6
1033	Myelodysplastic syndromes: an update on molecular pathology. 2010 , 12, 652-61	15
1032	Myelodysplastic syndrome: classification and prognostic systems. 2010 , 4, 25-33	5
1031	Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. 2010 , 91, 97-103	15
1030	Thalidomide is a highly effective treatment of MDS: a single-hospital experience in Japan. 2010 , 91, 725-7	3
1029	High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond. 2010 , 5, 1-8	7
1028	Cytogenetic Study of Myelodysplastic Syndrome. 2010 , 7, 46-50	
1027	Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. 2010 , 32, 2444-56	20
1026	Derivative (1)t(1;16)(p11;p11.1) in myelodysplastic syndrome: a case report and review of the literature. 2010 , 196, 89-92	1
1025	Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome. 2010 , 196, 159-66	20

1024	Adult B-cell acute lymphoblastic leukemia with two unrelated abnormal cytogenetic clones. 2010 , 201, 24-7	1
1023	Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome. 2010 , 38, 202-12	17
1022	In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome. 2010 , 38, 677-84	19
1021	Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndrome. 2010 , 38, 718-32, 732.e1-6	8
1020	Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. 2010 , 14, 895-902	47
1019	Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes*. 2010 , 84, 298-303	27
1018	Epigenetic therapy in myelodysplastic syndromes. 2010 , 84, 463-73	32
1017	Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. 2010 , 85, 130-8	95
1016	Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. 2010 , 85, 231-5	22
1015	Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome. 2010 , 32, 74-81	12
1014	The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion. 2010 , 49, 998-1013	39
1013	Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. 2010 , 116, 1485-94	85
1012	Cause of death in patients with lower-risk myelodysplastic syndrome. 2010 , 116, 2174-9	109
1011	Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. 2010 , 116, 2372-81	42
1010	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. 2010 , 116, 3830-4	195
1009	Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. 2010 , 116, 4549-63	73
1008	Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. 2010 , 116, 5420-31	334
1007	Nuclear inositide signaling in myelodysplastic syndromes. 2010 , 109, 1065-71	22

1006	Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes. 2010 , 77, 840-8	18
1005	Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. 2010 , 78, 154-68	29
1004	Bone marrow biopsy in patients with hepatitis C virus infection: spectrum of findings and diagnostic utility. 2010 , 85, 106-10	30
1003	Genetic polymorphisms in cytochrome P450s, GSTs, NATs, alcohol consumption and risk of non-Hodgkin lymphoma. 2010 , 85, 213-5	2
1002	Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. 2010 , 85, 160-3	19
1001	ASH 2009 meeting report—Top 10 clinically oriented abstracts in myeloproliferative neoplasms. 2010 , 85, NA-NA	
1000	ASH 2009 meeting report—Top 10 clinically-oriented abstracts in hematopoietic stem cell transplantation. 2010 , 85, NA-NA	
999	ASH 2009 meeting report—Top 10 clinically oriented abstracts in myelodysplastic syndromes. 2010 , 85, NA-NA	
998	ASH 2009 meeting report—Top 10 clinically oriented abstracts in coagulation medicine and platelet disorders. 2010 , 85, NA-NA	
997	ASH 2009 meeting report—Top 10 clinically oriented abstracts in sickle cell disease. 2010 , 85, NA-NA	
996	ASH 2009 meeting report—Top 10 clinically oriented abstracts in multiple myeloma. 2010 , 85, NA-NA	
995	Deciphering the path ahead in myelodysplastic syndrome. 2010 , 85, 157-8	1
994	ASH 2009 meeting report—Top 10 clinically oriented abstracts in chronic lymphocytic leukemia. 2010 , 85, NA-NA	
993	Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. 2010 , 85, 579-83	5
992	Outcome of patients with myelodysplastic syndromes in the Veterans Administration population. 2010 , 34, 59-62	12
991	Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study. 2010 , 34, 160-5	42
990	Incorporating novel agents in the treatment of myelodysplastic syndromes. 2010 , 34, 6-17	9
989	FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). 2010 , 34, 447-53	56

988	Right and left shifts for age in MDS. 2010 , 34, 409-10	1
987	FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes?. 2010 , 34, 420-5	38
986	ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. 2010 , 34, 598-604	23
985	Adding FISH to karyotype in Myelodysplastic syndrome investigation diagnosis: are all questions answered?. 2010 , 34, 413-5	3
984	Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes. 2010 , 34, 981-5	21
983	Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes. 2010 , 34, 974-80	21
982	Neutrophilic eccrine hidradenitis associated with decitabine. 2010 , 34, e130-2	6
981	Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. 2010 , 34, 986-90	23
980	Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). 2010 , 34, 864-70	150
979	Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome. 2010 , 34, 991-4	6
978	FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. 2010 , 34, 1296-301	26
977	Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. 2010 , 34, 1576-88	100
976	Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?. 2010 , 34, 1437-41	24
975	Improvement of the WHO classification-based prognostic scoring system (WPSS) by including age for Korean patients with the myelodysplastic syndrome. 2010 , 34, 1589-95	
974	Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?. 2010 , 34, 1242-5	20
973	Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1alpha-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes. 2010 , 34, 1151-7	13
972	Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS. 2010 , 34, 1610-6	29
971	Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. 2010 , 34, 1410-6	43

970	The lower risk MDS patient at risk of rapid progression. 2010 , 34, 1551-5	42
969	Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. 2010 , 34, 1560-5	38
968	Significance of JAK2 and TET2 mutations in myelodysplastic syndromes. 2010 , 24, 83-90	10
967	Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. 2010 , 76, 218-27	96
966	Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes. 2010 , 3, 23	27
965	Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts. 2010 , 3, 30	13
964	[Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors]. 2010 , 39, 217-27	
963	Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. 2010 , 50, 190-9	33
962	Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. 2010 , 148, 90-8	35
961	Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome. 2010 , 149, 322-33	27
960	Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. 2010 , 149, 244-9	65
959	Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes. 2010 , 149, 587-97	23
958	Current therapeutic approaches for patients with myelodysplastic syndromes. 2010 , 150, 131-43	23
957	Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. 2010 , 150, 293-302	49
956	Myelodysplastic syndromes: lost between two states?. 2010 , 24, 1-5	33
955	Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. 2010 , 24, 592-600	27
954	Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. 2010 , 24, 740-7	12
953	Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. 2010 , 24, 1528-32	122

952	BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia. 2010 , 24, 1429-36	32
951	Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. 2010 , 24, 756-64	197
950	Trisomy 11: prevalence among 22,403 unique patient cytogenetic studies and clinical correlates. 2010 , 24, 1092-4	6
949	5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. 2010 , 45, 255-60	108
948	Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. 2010 , 45, 450-7	29
947	Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. 2010 , 45, 633-9	38
946	Myeloablative hematopoietic stem cell transplantation for myelodysplastic syndrome in patients younger than 55 years: impact of comorbidity and disease burden on the long-term outcome. 2010 , 32, 222-9	18
945	Prognostic value of trisomy 8 in primary myelodysplastic syndrome. 2010 , 40, 697-703	5
944	Management of myelodysplasia in older adults. 221-229	
943	An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. 2010 , 3, 1-13	19
942	Blood Disorders in the Elderly. 2010 , 775-790	
941	Molecular Diagnostics of Hematopoietic Disorders. 2010 , 243-260	1
940	Myelodysplastic syndromes/neoplasms: recent classification system based on World Health Organization Classification of Tumors - International Agency for Research on Cancer for Hematopoietic and Lymphoid Tissues. 2010 , 1, 171-82	18
939	Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. 307-328	
938	Role and timing of hematopoietic cell transplantation for myelodysplastic syndrome. 2010 , 2, e2010019	1
937	Decreased CD10 Expression in the Bone Marrow Neutrophils of HIV Positive Patients. 2010 , 2, e2010032	2
936	Cytogénétique des syndromes myélodysplasiques et apport des techniques pangénomiques. 2010 , 16, 8-11	
935	Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia. 2010 , 2, e2010012	1

934	New treatments for myelodysplastic syndromes. 2010 , 2, e2010021	4
933	Myelodysplastic syndromes and the role of iron overload. 2010 , 67, S3-9	3
932	Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. 2010 , 28, 562-9	756
931	Reply to F. Damm et al. 2010 , 28, e388-e389	1
930	Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. 2010 , 21, 120-5	49
929	Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. 2010 , 2010, 164045	36
928	Iron chelation therapy in myelodysplastic syndromes. 2010 , 2010, 756289	9
927	Immune dysregulation in myelodysplastic syndrome. 2010 , 2, e1	14
926	ESMO Handbook of Cancer in the Senior Patient. 2010 ,	5
925	Therapy with azanucleosides for myelodysplastic syndromes. 2010 , 7, 433-44	67
924	Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. 2010 , 51, 783-8	15
923	Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. 2010 , 13, 559-70	9
922	Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. 2010 , 10, 1663-72	29
921	Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. 2010 , 28, 2253-8	113
920	Phosphoinositide phospholipase Cbeta1 (PI-PLCbeta1) gene in myelodysplastic syndromes and cytogenetically normal acute myeloid leukemia: not a deletion, but increased PI-PLCbeta1 expression is an independent prognostic factor. 2010 , 28, e384-7; author reply e388-9	3
919	Case records of the Massachusetts General Hospital. Case 27-2010. A 73-year-old woman with chronic anemia. 2010 , 363, 1060-8	1
918	5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis. 2010 , 95, 303-10	74
917	Closing in on the pathogenesis of the 5q- syndrome. 2010 , 10, 655-8	5

916	Decitabine in the treatment of myelodysplastic syndromes. 2010 , 10, 9-22	50
915	Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. 2010 , 28, 2755-60	48
914	Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. 2010 , 28, 1878-87	385
913	An update on the treatment of myelodysplastic syndromes. 2010 , 14, E29-44	10
912	[Clinical and prognostic significance of CD34 expression in bone marrow biopsies in myelodysplastic syndrome]. 2010 , 63, 487-91	
911	Array comparative genomic hybridization of peripheral blood granulocytes of patients with myelodysplastic syndrome detects karyotypic abnormalities. 2010 , 134, 119-26	11
910	The hematopoietic growth factors in the myelodysplastic syndromes. 2011 , 157, 363-82	1
909	Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. 2010 , 45, 1300-8	12
908	HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome. 2010 , 45, 1333-9	24
907	Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. 2010 , 45, 1611-7	8
906	Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8. 2010 , 40, 1037-45	23
905	Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. 2010 , 21, 114-9	91
904	Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. 2010 , 95, 1308-16	103
903	Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?. 2010 , 2010, 322-4	
902	Prognosis of myelodysplastic syndromes. 2010 , 2010, 330-7	19
901	Low-dose melphalan in myelodysplastic syndromes: an effective treatment for elderly RAEB-I or II patients?. 2010 , 51, 549-51	2
900	Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. 2010 , 45, 1502-7	44
899	[Current treatment options for myelodysplastic syndromes]. 2010 , 135, 1863-9	

898	Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond. 2010 , 10, 605-14	10
897	Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. 2010 , 28, 437-44	154
896	[Acute respiratory distress revealing acute myeloblastic leukaemia: case report]. 2010 , 66, 276-80	
895	Myelodysplastic syndromes--many new drugs, little therapeutic progress. 2010 , 85, 1042-5	11
894	Hematopoietic stem cell transplantation for MDS. 2010 , 24, 407-22	27
893	The genetic basis of myelodysplastic syndromes. 2010 , 24, 295-315	25
892	Prognostic classification and risk assessment in myelodysplastic syndromes. 2010 , 24, 459-68	34
891	Diagnosis of Myelodysplastic Syndromes in Cytopenic Patients. 2010 , 3, 1127-52	1
890	Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. 2010 , 19, 1043-54	55
889	Myelodysplastic Syndromes. 2010 , 141-178	
888	Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization. 2010 , 203, 193-202	5
887	Myelodysplastic syndromes: a practical approach to diagnosis and treatment. 2010 , 77, 37-44	28
886	Current and future management options for myelodysplastic syndromes. 2010 , 70, 1381-94	9
885	Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study. 2010 , 133, 260-4	37
884	Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. 2010 , 51, 2250-7	12
883	Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome. 2010 , 2010, 325-9	17
882	Approaches to Classification of Lymphoma and Leukemia. 2010 , 3-20	1
881	Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms. 2010 , 123-144	

880	[Massive skin infiltration followed by central nervous system infiltration in a patient with chronic myelomonocytic leukemia]. 2010 , 135, 186-7		1
879	Are we nearer to curing patients with MDS?. 2010 , 23, 481-7		8
878	Myelodysplastic syndromes: what a primary care physician needs to know. 2010 , 56, 468-78		1
877	The evolving clinical scenario of myelodysplastic syndrome: the need for a complete and up to date upfront diagnostic assessment. 2010 , 21, 490-5		6
876	Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes. 2010 , 16, 1-11		8
875	Hematopoietic stem cell transplantation for myelodysplastic syndrome. 2010 , 16, S37-44		10
874	Myelodysplastic syndromes: from neglect to prominence. 2010 , 16, S28-9		
873	Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. 2010 , 16, 792-800		68
872	Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. 2010 , 45, 181-5		24
871	NF- κ B as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. 2010 , 14, 1157-76		38
870	Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. <i>Blood</i> , 2010 , 116, 4077-85	2.2	157
869	Epigenetic changes in the myelodysplastic syndrome. 2010 , 24, 317-30		80
868	Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. 2010 , 45, 877-85		43
867	Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. 2010 ,		1
866	Deferasirox for managing iron overload in people with myelodysplastic syndrome. 2010 , CD007461		3
865	Myelodysplastic syndromes classification and risk stratification. 2010 , 24, 443-57		48
864	Myelodysplastic syndromes. 2010 , 61, 345-58		41
863	GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies. 2010 , 29, 111		10

862	Refractory cytopenias with unilineage dysplasia: a retrospective analysis of refractory neutropenia and refractory thrombocytopenia. 2010 , 51, 1923-6		8
861	Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. 2010 , 51, 1007-14		31
860	Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2011 , 118, 6239-46	2.2	365
859	Clofarabine for myelodysplastic syndromes. 2011 , 20, 1005-14		
858	Cytogenetic risk stratification in chronic myelomonocytic leukemia. 2011 , 96, 375-83		186
857	Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. 2011 , 96, 441-9		180
856	Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT. 2011 , 46, 719-26		13
855	Hypomethylating agents and other novel strategies in myelodysplastic syndromes. 2011 , 29, 516-23		116
854	Myelodysplastic syndromes. 2011 , 31, 763-84		6
853	Unraveling the molecular pathophysiology of myelodysplastic syndromes. 2011 , 29, 504-15		241
852	Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. 2011 , 27, 951-60		26
851	Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. 2011 , 11, 237-41		14
850	External validation of newly proposed cytogenetic risk classification in patients who have myelodysplastic syndrome: a retrospective analysis at a single institution. 2011 , 11, 273-9		
849	Standard therapy for patients with myelodysplastic syndromes. 2011 , 11, 303-13		3
848	Physiology and pathology of nuclear phospholipase C β . 2011 , 51, 2-12		16
847	Cytogenetics of MDS. 2011 , 55-85		1
846	Cytogenetic analysis and reporting. 2011 , 730, 259-68		2
845	[From conventional cytogenetics to microarrays. Fifty years of Philadelphia chromosome]. 2011 , 137, 221-9		2

844	Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments. 2011 , 71, 155-77	14
843	Large vessel (Takayasu's) arteritis in a patient with myelodysplastic syndrome: is there a common pathogenesis?. 2011 , 11, 60-3	13
842	Encyclopedia of Cancer. 2011 , 2259-2259	
841	Encyclopedia of Cancer. 2011 , 2258-2259	
840	Cancer Cytogenetics. 2011 ,	1
839	Two different del(5q) clones in a patient with myelodysplastic syndrome. 2011 , 52, 1811-4	1
838	Hematopoietic Growth Factors in Oncology. 2011 ,	5
837	Diagnosis of myelodysplastic syndromes in cytopenic patients. 2011 , 25, 1085-110, vii	6
836	Oncogfatrie. 2011 ,	
835	Le sindromi mielodisplastiche: diagnosi, prognosi e terapia. 2011 , 5, 90-97	1
834	A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia. 2011 , 13, 1035-42	16
833	5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline. 2011 , 37, 160-7	23
832	The role of hematopoietic cell transplantation as therapy for myelodysplasia. 2011 , 24, 541-7	5
831	A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes. 2011 , 204, 187-94	23
830	Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes. 2011 , 204, 603-28	54
829	Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. 2011 , 17, 341-50	80
828	Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. 2011 , 17, 908-15	91
827	Clofarabine + fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. 2011 , 17, 893-900	76

826	Hematopoietic stem cell transplantation for treatment of myelodysplastic syndromes. 2011 , 17, S6-8	0
825	[Myelodysplastic syndrome with erythroblastopenia]. 2011 , 32, 33-8	2
824	Apport de l'hybridation in situ en fluorescence (FISH) pour la détection des anomalies cytogénétiques dans les syndromes myélodysplasiques. 2011 , 2011, 65-72	
823	Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature. 2011 , 11, 293-7	6
822	Clinical effect of point mutations in myelodysplastic syndromes. 2011 , 364, 2496-506	1169
821	Myelodysplastic syndromes. 2011 , 28, 258-72	11
820	The epigenomics revolution in myelodysplasia: a clinico-pathological perspective. 2011 , 43, 536-46	8
819	SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. 2018 , 23, 355-369.e9	46
818	Part 2: Myelodysplastic syndromes - classification systems. 2018 , 40, 262-266	0
817	Impacts of demographic and laboratory parameters on key hematological indices in an adult population of southern Taiwan: A cohort study. 2018 , 13, e0201708	2
816	Myelodysplastic Syndromes. 2018 ,	
815	Treatment with Hypomethylating Agents (HMA). 2018 , 131-139	
814	Allogeneic Stem Cell Transplantation for MDS. 2018 , 141-157	
813	Chronic Myelomonocytic Leukemia (CMML). 2018 , 65-79	
812	Prognostic impact of elevated pretreatment serum ferritin in patients with high-risk MDS treated with azacitidine. 2018 , 65, 34-37	7
811	Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. 2018 , 74, 137-143	5
810	Cytogenetics of MDS. 2018 , 43-64	
809	Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML. 2018 , 70, 74-78	10

808	Myelodysplastic Syndrome Updated. 2019 , 86, 7-13	20
807	The Molecular Pathology of Myelodysplastic Syndrome. 2019 , 86, 24-29	16
806	Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care. 2019 , 60, 49-59	2
805	Prognostic significance of monosomal karyotype in myelodysplastic syndrome: a meta-analysis. 2019 , 24, 60-69	2
804	Reduced regulatory T cells (Treg) in bone marrow preferentially associate with the expansion of cytotoxic T lymphocytes in low risk MDS patients. 2019 , 185, 357-360	7
803	Androgen therapy for patients with lower-risk myelodysplastic syndrome and significant cytopenia: a retrospective study. 2019 , 187, e4-e7	1
802	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. 2019 , 98, 2319-2328	3
801	Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients. 2019 , 9, 63	13
800	Novel therapies in low- and high-risk myelodysplastic syndrome. 2019 , 12, 893-908	9
799	HIV portends a poor prognosis in myelodysplastic syndromes. 2019 , 60, 3529-3535	10
798	Enhanced polo-like kinase 1 expression in myelodysplastic syndromes. 2019 , 54, 102-107	
797	Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes. 2019 , 12, 821-831	5
796	Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. 2019 , 25, 2366-2374	0
795	Immune Dysregulation in MDS: The Role of Cytokines and Immune Cells. 2019 ,	0
794	Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome. 2019 , 191-201	
793	Effect of L-Leucine Therapy on Hematopoietic Function in Elderly Myelodysplastic Syndrome Patients. 2019 , 42, 1651-1657	2
792	Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. 2019 , 110, 533-542	4
791	Myelodysplastic Syndromes: An Update on Pathophysiology and Management. 2019 ,	

790	Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. 2019 , 19, 656-664		4
789	When karyotype is decisive for myelodysplastic syndromes diagnosis. 2019 , 41, 371-373		
788	Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies. 2019 , 11,		8
787	The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q. 2019 , 3, 351-358		2
786	Design of a Soft Wearable Device for Hip and Knee Extension Assistance. 2019 ,		4
785	Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression. 2019 , 68, 2015-2027		17
784	Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS. 2019 , 9, 86		16
783	Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. 2019 , 94, 1344-1352		4
782	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. 2019 , 94, 1467-1474		8
781	Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis. 2019 , 8, 7567-7576		3
780	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. 2019 , 84, 106191		2
779	In myelodysplastic syndrome cases, what should be the level of ferritin which has prognostic value?. 2019 , 26, 217-223		0
778	The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine. 2019 , 145, 3089-3097		1
777	Rethinking clinical trial endpoints in myelodysplastic syndromes. 2019 , 33, 570-575		8
776	The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. <i>Blood</i> , 2019 , 133, 1039-1048	2.2	90
775	MDS overlap disorders and diagnostic boundaries. <i>Blood</i> , 2019 , 133, 1086-1095	2.2	32
774	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. 2019 , 104, 929-936		12
773	A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. 2019 , 19, 157-161		23

772	Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres. 2019 , 54, 1434-1442	3
771	Wilms tumor 1 expression: addressing the 'elephant' in MDS. 2019 , 60, 566-567	
770	Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS. 2019 , 14, 346-351	9
769	Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in , and - azacitidine induces only lymphoma remission. 2019 , 60, 3316-3319	7
768	Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy. 2019 , 83, 106170	7
767	Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. 2019 , 19, 617	27
766	A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome. 2019 , 13, 1821-1833	3
765	Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity. 2019 , 187, 93-104	10
764	Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. 2019 , 98, 1919-1925	8
763	Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. 2019 , 141, 54-72	12
762	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. 2019 , 46, 1902-1910	26
761	The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. 2019 , 60, 3161-3171	6
760	Monosomal karyotypes apart from complex karyotypes independently predict the outcome of myelodysplastic syndrome patients using a fluorescence in situ hybridization panel and conventional cytogenetics. 2019 , 41, 519-529	3
759	Flow cytometry "Ogata score" for the diagnosis of myelodysplastic syndromes in a real-life setting. A Latin American experience. 2019 , 41, 536-541	4
758	Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. 2019 , 19, e367-e373	0
757	Factors predicting early mortality after new diagnosis of myelodysplastic syndrome: A population-based study. 2019 , 103, 56-63	3
756	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. 2019 , 6, e317-e327	54
755	Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment. 2019 , 14, 154-163	8

754	Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes: a diagnostic accuracy study. 2019 , 104, 2382-2390	2
753	Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. 2019 , 81, 43-49	4
752	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. 2019 , 60, 2483-2487	2
751	Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome. 2019 , 60, 2762-2770	6
750	Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine. 2019 , 8, 2188-2195	5
749	Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. 2019 , 58, 689-697	4
748	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. 2019 , 133-188	1
747	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. 2019 , 104, 1935-1949	58
746	Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia. 2019 , 25, 1550-1559	29
745	Enhanced Renewal of Erythroid Progenitors in Myelodysplastic Anemia by Peripheral Serotonin. 2019 , 26, 3246-3256.e4	11
744	Immunophenotypic Features of Myeloid Neoplasms Associated with Chromosome 7 Abnormalities. 2019 , 96, 300-309	4
743	Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation. 2019 , 9, 31	3
742	Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. 2019 , 98, 1367-1381	6
741	Gender disparity in the survival of patients with primary myelodysplastic syndrome. 2019 , 10, 1325-1332	9
740	Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review. 2019 , 136, 37-47	6
739	Treatment of myelodysplastic syndrome in the era of next-generation sequencing. 2019 , 286, 41-62	8
738	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. 2019 , 98, 1383-1392	8
737	Comprehensive molecular characterization of myeloid malignancies with 9q deletion. 2019 , 60, 2591-2593	0

736	Prognostic Impact of Immunohistochemical p53 Expression in Bone Marrow Biopsy in Higher Risk MDS: a Pilot Study. 2019 , 11, e2019015	5
735	Getting personal with myelodysplastic syndromes: is now the right time?. 2019 , 12, 215-224	7
734	Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols. 2019 , 81, 35-42	6
733	Pretreatment CD34/CD38 Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation. 2019 , 25, 1560-1566	2
732	Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. 2019 , 186, 86-90	3
731	A phase 2 trial of the oral smoothed inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). 2019 , 81, 56-61	19
730	Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms. 2019 , 25, 1293-1303	11
729	Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine. 2019 , 60, 2457-2463	8
728	Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?. 2019 , 32, 104-113	3
727	Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation. 2019 , 54, 1471-1481	2
726	A diagnosis of discernment: Identifying a novel ATRX mutation in myelodysplastic syndrome with acquired β -thalassemia. 2019 , 231-232, 36-40	1
725	Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes. 2019 , 102, 442-443	1
724	Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics. 2019 , 2, e48	6
723	In MDS, is higher risk higher reward?. 2019 , 2019, 381-390	1
722	Integrating patient-centered factors in the risk assessment of MDS. 2019 , 2019, 373-380	5
721	Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. 2019 , 3, e314	11
720	Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?. 2019 , 3, 3449-3453	4
719	mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. 2019 , 3, 922-933	39

718	Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. 2019 , 3, 980-983	2
717	Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. 2019 , 21, 101	8
716	Does mutational burden add to other prognostic factors in MDS?. 2019 , 32, 101098	2
715	Mutation-Driven Therapy in MDS. 2019 , 14, 550-560	4
714	Application of Genomics to Clinical Practice in Haematological Malignancy. 2019 , 7, 236-252	
713	Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogeneic transplantation. 2019 , 54, 288-290	
712	Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity. 2019 , 38, 687-698	11
711	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. 2019 , 25, 114-120	14
710	Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC. 2019 , 67, 8-15	3
709	Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome. 2019 , 60, 703-710	6
708	Molecular pathogenesis of myelodysplastic syndromes with deletion 5q. 2019 , 102, 203-209	13
707	Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). 2019 , 19, 1-8	5
706	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. 2019 , 33, 379-389	287
705	Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. 2019 , 104, 700-709	5
704	Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes. 2019 , 77, 8-13	
703	Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. <i>Blood</i> , 2019 , 133, 790-794	2.2 50
702	Reduced-Toxicity Myeloablative Conditioning Consisting of Fludarabine/Busulfan/Low-Dose Total Body Irradiation/Granulocyte Colony-Stimulating Factor-Combined Cytarabine in Single Cord Blood Transplantation for Elderly Patients with Nonremission Myeloid Malignancies. 2019 , 25, 764-770	13
701	Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review. 2019 , 18, 36-42	16

700	Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. 2019 , 60, 1721-1730	7
699	Anemia in the Young and Old. 2019 ,	
698	Myelodysplastic Syndromes (MDS). 2019 , 333-341	
697	Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia. 2019 , 98, 1127-1133	
696	Analysis of clinical and molecular features of MDS patients with complex karyotype in China. 2019 , 75, 13-19	6
695	Calculator-free point-of-care prognostication in myelodysplastic syndromes. 2019 , 94, E99-E101	
694	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. 2019 , 54, 1281-1286	17
693	Does Double Mutation Portend Better or Worse Prognosis Than Isolated or Mutation?. 2019 , 16, 91-98	3
692	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". 2019 , 94, 475-488	23
691	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. 2019 , 33, 1747-1758	88
690	An update on treatment of higher risk myelodysplastic syndromes. 2019 , 12, 61-70	1
689	Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis. 2019 , 37, 85-95	4
688	A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. 2019 , 94, 74-79	4
687	Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. 2019 , 54, 1245-1253	6
686	Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. 2019 , 60, 1522-1527	2
685	From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes. 2019 , 58, 474-483	5
684	Effect of Qinghuang Powder () Combined with Bupi Yishen Decoction () in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation. 2019 , 25, 354-359	4
683	Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. 2020 , 11, 114-120	16

682	Context is everything: aneuploidy in cancer. 2020 , 21, 44-62	145
681	Iron Support in Erythropoietin Treatment in Myelodysplastic Syndrome Patients Affected by Low-Risk Refractory Anaemia: Real-Life Evidence from an Italian Setting. 2020 , 143, 155-162	2
680	Prospective Phase 2 Study of Umbilical Cord Blood Transplantation in Adult Acute Leukemia and Myelodysplastic Syndrome. 2020 , 26, 139-144	3
679	Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacytidine: Results From the Hellenic 5-Azacytidine Registry. 2020 , 20, 114-121	2
678	A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. 2020 , 188, 404-412	6
677	Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allograft: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. 2020 , 26, 451-457	8
676	Myelodysplastic syndromes. 2020 , 589-602	
675	Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. 2020 , 11, 121-124	4
674	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. 2020 , 34, 656-661	17
673	Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. 2020 , 34, 872-881	6
672	The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. 2020 , 99, 7-19	6
671	How we manage adults with myelodysplastic syndrome. 2020 , 189, 1016-1027	28
670	The evolving role of next generation sequencing in myelodysplastic syndromes. 2020 , 188, 224-239	7
669	Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation. 2020 , 98, 131-145	15
668	Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population. 2020 , 11, 508-519	4
667	Myelodysplastic Syndromes. 2020 , 1798-1820.e11	
666	Moving towards a uniform risk stratification system in CMML - How far are we?. 2020 , 33, 101131	1
665	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. 2020 , 382, 140-151	160

664	Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study. 2020 , 10, 39	5
663	Contemporary treatment approaches to CMML - Is allogeneic HCT the only cure?. 2020 , 33, 101138	1
662	Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity. 2020 , 34, 379-391	0
661	Reduced PLAGL1 expression is associated with inferior survival for myelodysplastic syndromes. 2020 , 9, 460-468	3
660	Allogeneic stem cell transplant in myelodysplastic syndrome-factors impacting survival. 2020 , 104, 116-124	4
659	An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. 2020 , 34, 1394-1406	15
658	Combining gene variants with clinical characteristics improves outcome prediction in Chinese patients with myelodysplastic syndromes. 2020 , 61, 919-926	3
657	Hypomethylation of MIR-378 5'-flanking region predicts poor survival in young patients with myelodysplastic syndrome. 2020 , 8, e1067	2
656	Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome. 2020 , 73, 209-212	2
655	Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome. 2020 , 59, 1081-1086	2
654	Novel Prognostic Models for Myelodysplastic Syndromes. 2020 , 34, 369-378	3
653	Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. <i>Blood</i> , 2020 , 136, 2249-2262	2.2 21
652	Chromosome 3p loss of heterozygosity and reduced expression of H3K36me3 correlate with longer relapse-free survival in sacral conventional chordoma. 2020 , 104, 73-83	2
651	Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins. 2020 , 21,	6
650	Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications. 2020 , 96, 106419	3
649	Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes. 2020 , 14, 2403-2419	3
648	Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?. 2020 , 34, 2552-2560	2
647	Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. 2020 , 60, 1867-1872	

646	No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki. 2020 , 111, 4490-4499	1
645	Serum Inflamm-miR Signature: A Biomarker of Myelodysplastic Syndrome?. 2020 , 10, 595838	1
644	Síndromes mielodisplásicos. 2020 , 24, 1-7	
643	Emerging treatment options for patients with high-risk myelodysplastic syndrome. 2020 , 11, 2040620720955086	
642	Patient stratification in myelodysplastic syndromes: how a puzzle may become a map. 2020 , 2020, 418-425	3
641	Therapy for lower-risk MDS. 2020 , 2020, 426-433	13
640	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. 2020 , 4, 5580-5588	42
639	Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. 2020 , 172, 513-522	37
638	Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes. 2020 , 10, 19555	5
637	The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. 2020 , 95, 1361-1367	7
636	Identification of latent core genes and pathways associated with myelodysplastic syndromes based on integrated bioinformatics analysis. 2020 , 25, 299-308	4
635	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. 2020 , 95, 1457-1465	1
634	Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome. 2020 , 14, 100215	3
633	Prognostic Markers of Myelodysplastic Syndromes. 2020 , 56,	4
632	Improving the accuracy of prognostication in chronic myelomonocytic leukemia. 2020 , 20, 703-714	2
631	Founder and subclonal mutations in myelodysplastic syndromes and related myeloid neoplasms. 2020 , 33, 101189	2
630	Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. 2020 , 95, 1399-1420	32
629	Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia. 2020 , 154, 103067	1

628	Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia. 2020 , 97, 106430	5
627	Diagnosis and Management of Myelodysplastic Syndromes. 2020 ,	
626	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. 2020 , 26, 2139-2146	6
625	Controversies on the Consequences of Iron Overload and Chelation in MDS. 2020 , 4, e357	7
624	Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes. 2020 , 26, e263-e264	
623	Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of. 2020 , 13, 10143-10148	
622	Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?. 2020 , 13, 1131-1142	3
621	Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS). 2020 , 34, 15400-15416	1
620	Guideline-based indicators for adult patients with myelodysplastic syndromes. 2020 , 4, 4029-4044	2
619	Revised 15-item MDS-specific frailty scale maintains prognostic potential. 2020 , 34, 3434-3438	5
618	Transformation of CMML to AML presenting with acute kidney injury. 2020 , 10, 353-357	1
617	Relationship between p53 expression and prognosis of myelodysplastic syndrome treated with azacitidine. 2020 , 13, 213-219	
616	Effects of Acute and Chronic Graft-versus-myelodysplastic Syndrome on Long-term Outcomes Following Allogeneic Hematopoietic Cell Transplantation. 2020 , 26, 6483-6493	3
615	Development of Telintra as an Inhibitor of Glutathione S-Transferase P. 2021 , 264, 71-91	6
614	Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome. 2020 , 112, 825-834	1
613	Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. 2020 , 11, 2040620720966121	4
612	Emerging drugs for the treatment of chronic myelomonocytic leukemia. 2020 , 25, 515-529	1
611	Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. 2020 , 99, 106472	2

610	Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?. 2020 , 61, 2295-2312		5
609	Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. 2020 , 15, 194-202		4
608	The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. 2020 , 95, 1006-1014		24
607	Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years. 2020 , 20, 465-482		3
606	[Treatment of secondary acute myeloid leukemia with azacitidine : Maintenance of quality of life and independence in advanced age]. 2020 , 53, 362-364		
605	Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. 2020 , 94, 106369		11
604	Genetics of progression from MDS to secondary leukemia. <i>Blood</i> , 2020 , 136, 50-60	2.2	26
603	How I Diagnose Low-Grade Myelodysplastic Syndromes. 2020 , 154, 5-14		3
602	Transfusional iron overload in patients with myelodysplastic syndromes: A 10-year retrospective survey from a French general hospital. 2020 , 27, 128-132		0
601	Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study. 2020 , 61, 1688-1694		1
600	Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. 2020 , 61, 1678-1687		3
599	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. 2020 , 7, e309-e319		40
598	Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. 2020 , 13, 447-460		1
597	Novel combinations to improve hematopoiesis in myelodysplastic syndrome. 2020 , 11, 132		1
596	Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification. 2020 , 13, 79-88		1
595	Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2020 , 136, 1851-1862	2.2	34
594	Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?. 2020 , 13, 233-239		1
593	Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. 2020 , 34, 2441-2450		6

592	Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes. 2020 , 60, 879-888	
591	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. 2020 , 34, 2451-2459	9
590	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. 2020 , 126, 2193-2205	17
589	Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. 2020 , 15, 268-275	3
588	Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'. 2020 , 61, 1445-1454	2
587	LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. 2020 , 61, 1493-1499	9
586	Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health Span. 2020 , 15, 149-154	1
585	Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. 2020 , 20, 324-328	3
584	SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia. 2020 , 20, 329-339.e3	2
583	Clinical effects of the CD13/CD33 ratio on the prognosis of myelodysplastic syndrome treated with azacitidine. 2020 , 61, 1250-1253	2
582	Bloodstream infection by multidrug-resistant Streptococcus oralis in a leukemic patient with febrile neutropenia after hematopoietic stem cell transplantation. 2020 , 22, e13246	0
581	A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations. 2020 , 10, 826	4
580	Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase. 2020 , 86, 991-998	3
579	PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes. 2020 , 104, 526-537	1
578	CD177 Enhances the Detection of Myelodysplastic Syndrome by Flow Cytometry. 2020 , 153, 554-565	4
577	The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome. 2020 , 21,	3
576	Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. 2020 , 93, 106367	11
575	Decision Analysis of Transplantation for Patients with Myelodysplasia: "Who Should We Transplant Today?". 2020 , 15, 305-315	1

574	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. 2020 , 61, 1943-1953	1
573	Balanced translocations in myelodysplastic syndromes (MDS) - an unrecognised MDS patient subgroup?. 2020 , 190, 141-142	1
572	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. 2020 , 4, 482-495	36
571	A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients. 2020 , 4, 644-654	8
570	Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells. 2021 , 106, 555-564	12
569	Therapeutic strategies in low and high-risk MDS: What does the future have to offer?. 2021 , 45, 100689	9
568	Treating Leukemia in the Time of COVID-19. 2021 , 144, 132-145	37
567	Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia. 2021 , 100, 63-78	1
566	5-Azacytidine restores interleukin 6-increased production in mesenchymal stromal cells from myelodysplastic patients. 2021 , 43, 35-42	7
565	Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation. 2021 , 56, 129-136	5
564	Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome. 2021 , 192, 729-736	5
563	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. 2021 , 35, 835-849	20
562	Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes. 2021 , 100, 455-463	2
561	Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences. 2021 , 46, 100735	4
560	Increased proportion and altered properties of intermediate monocytes in the peripheral blood of patients with lower risk Myelodysplastic Syndrome. 2021 , 86, 102507	0
559	Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse. 2021 , 21, 1-7	6
558	Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2021 , 32, 142-156	17
557	The expression levels of long non-coding RNA KIAA0125 are associated with distinct clinical and biological features in myelodysplastic syndromes. 2021 , 192, 589-598	1

- 556 Parsing the Paradox of Myelodysplastic Syndromes. **2021**, 39, 4-6
- 555 Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. **2021**, 35, 1166-1175 2
- 554 Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival. **2021**, 48, 1390-1398 7
- 553 Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. **2021**, 10, 447-453 2
- 552 The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. **2021**, 192, 978-987 0
- 551 LINC01255 combined with BMI1 to regulate human mesenchymal stromal senescence and acute myeloid leukemia cell proliferation through repressing transcription of MCP-1. **2021**, 23, 1105-1116 1
- 550 Discontinuation of the renin-angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes. **2021**, 12, 2040620720958299
- 549 Intracellular ROS profile in hematopoietic progenitors of MDS patients: association with blast count and iron overload. **2021**, 26, 88-95 0
- 548 Integration Analysis of or Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic Syndrome. **2020**, 10, 610525 1
- 547 HSCT in Malignancies. **2021**, 99-114
- 546 Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PoLAZA'. **2021**, 26, 556-564 1
- 545 Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation. **2020**, 11, 603956 0
- 544 Next-Generation Sequencing Myeloid Panel Test for Patients with AML and MDS: Experience in a Tertiary Care Hospital. **2021**, 11, 40-46 0
- 543 Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management". **2021**, 96, 379-394 8
- 542 Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. **2021**, 127, 1598-1605 3
- 541 Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review. **2021**, 26, 312-320 0
- 540 Treatment options for lower-risk myelodysplastic syndromes. Where are we now?. **2021**, 12, 2040620720986641
- 539 Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. **2021**, 13, 645-657 2

538	Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. 2021 , 41, 333-344	3
537	A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS. 2021 , 21, 134	3
536	Autophagy Gene Panel-Based Prognostic Model in Myelodysplastic Syndrome. 2020 , 10, 606928	0
535	Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression for ruling out myelodysplastic syndromes: a prospective validation study. 2021 , 100, 1149-1158	0
534	Clinicopathologic Features of Myelodysplastic Syndromes Involving Lymph Nodes. 2021 , 45, 930-938	
533	Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes. 2021 ,	5
532	When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis. 2021 , 10,	2
531	Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). 2021 , 13,	3
530	Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs. 2021 , 118,	3
529	Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia. 2021 , 16, 247-255	1
528	The prognostic significance of single-nucleotide polymorphism array-based whole-genome analysis and uniparental disomy in myelodysplastic syndrome. 2021 , 43, 1062-1069	3
527	Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes. 2021 , 41, 328-350	0
526	Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. 2021 , 127, 2015-2024	0
525	Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome. 2021 , 36, 413-423	1
524	Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patients: insights from an Italian network. 2021 , 100, 1139-1147	1
523	Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists. 2021 , 22,	1
522	The role of Src homology region 2 domain-containing phosphatase-1 hypermethylation in the classification of patients with myelodysplastic syndromes and its association with signal transducer and activator of transcription 3 phosphorylation in skm-1 cells. 2021 , 49, 300060521999550	1
521	Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. 2021 , 39, 1001-1009	8

520	Precision medicine in myeloid malignancies. 2021 ,	5
519	Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study. 2021 , 100, 1451-1457	2
518	Autoimmune manifestations associated with myelodysplastic syndrome predict a poor prognosis. 2021 , 100, e25406	4
517	Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia. 2021 , 26, 406-421	1
516	A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms. 2021 , 13,	0
515	Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome. 2021 , 53, 328-338	1
514	Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome. 2021 , 103, 106540	1
513	Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. 2021 , 62, 2438-2447	
512	Prognostic relevance of lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience. 2021 , 62, 2272-2275	
511	Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal?. 2021 , 103, 106543	1
510	Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis. 2021 , 107, 3-23	3
509	Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. 2021 , 5, 2264-2271	3
508	Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS). 2021 , 2, 217-236	1
507	Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine. 2021 , 2021, 6640597	1
506	Luspatercept in the treatment of lower-risk myelodysplastic syndromes. 2021 , 17, 1473-1481	2
505	Current challenges and unmet medical needs in myelodysplastic syndromes. 2021 , 35, 2182-2198	6
504	Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes. 2021 , 107, 219-228	0
503	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. 2021 , 39, 1426-1436	17

502	Current Therapy of the Patients with MDS: Walking towards Personalized Therapy. 2021 , 10,	1
501	Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2. 2021 , 149, 1109-1120	1
500	Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes. 2021 , 21, 546	3
499	A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. 2021 , 104, 106555	1
498	Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients. 2021 , 100, 1439-1449	0
497	Myelodysplastic syndrome and immunotherapy novel to next in-line treatments. 2021 , 17, 2602-2616	1
496	Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned. 2021 , 50, 100851	0
495	Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration. 2021 , 10,	0
494	Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. 2021 , 56, 2510-2517	0
493	Survival Benefit and Efficiency of Low Dose Decitabine With CEG Regimen Compared to Decitabine Alone in the Elderly MDS - A Multicenter, Retrospective Study. 2021 , 21, e792-e800	
492	What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. 2021 , 62, 2762-2767	1
491	Prognostic value of disease risk score versus gait speed in older adults with lymphoma. 2021 , 62, 2882-2889	
490	Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia. 2021 , 17, 2077-2087	5
489	A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia. 2021 , 105, 106573	1
488	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. 2021 , 39, 3328-3339	14
487	Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. 2021 , 13,	0
486	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. 2021 , 35, 3542-3550	13
485	British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes. 2021 , 194, 282-293	4

- 484 Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation. **2021**, 194, 403-413 1
- 483 Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity. **2021**, 56, 102-108
- 482 The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study.. **2022**, 38, 299-308
- 481 Sindromi mielodisplastiche. **2021**, 23, 1-7
- 480 Stem Cells in the Myelodysplastic Syndromes. **2021**, 2, 3
- 479 Chronic Myelomonocytic Leukemia Gold Jubilee. **2021**, 2, 403-428
- 478 Increased serum C-reactive protein is an adverse prognostic factor in low-risk myelodysplastic syndromes. **2021**, 114, 441-448 2
- 477 Methylation of dual-specificity phosphatase 4 controls cell differentiation. **2021**, 36, 109421 2
- 476 The Genetics of Myelodysplastic Syndromes: Clinical Relevance. **2021**, 12, 2
- 475 On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation. **2021**, 0
- 474 Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). **2021**, 39, 3318-3327 7
- 473 Genetics of Myelodysplastic Syndromes. **2021**, 13, 2
- 472 Targeting the Myeloid Lineages and the Immune Microenvironment in Myelodysplastic Syndromes: Novel and Evolving Therapeutic Strategies. **2021**, 10600280211036154 0
- 471 The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant. **2021**, 56, 2749-2754
- 470 80/m mit zunehmender Belastungsdyspnoe und Abgeschlagenheit. **2021**, 27, 49-54
- 469 Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae. **2021**, 163, 103367 2
- 468 Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine. **2021**, 13, 1129-1143 0
- 467 Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients. **2021**, 100, 2575-2584 0

466	Current and emerging strategies for management of myelodysplastic syndromes. 2021 , 48, 100791	8
465	Cytogenetic and Genetic Advances in Myelodysplasia Syndromes.	
464	The impact of CD33/CD34 ratio in the prognosis of myelodysplastic syndrome treated with azacitidine for first-line therapy. 2021 , 14, 205-212	
463	Retrospective observation of the efficacy and safety of prostatic artery embolization combined with transurethral resection of the prostate and simple transurethral resection of the prostate in the treatment of large (> 100 mL) benign prostatic hyperplasia. 2021 , 46, 5746-5757	0
462	Expanding the immune armoury against myelodysplastic syndrome. 2021 , 195, 301-303	
461	Allogeneic Stem Cell Transplantation for MDS. 2021 , 2, 545-555	2
460	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. 2021 , 39, 3737-3746	14
459	Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. 2021 , 195, 378-387	8
458	SCOPIUS VERİTABANINA DAYALI BİLİMİYOLOJİK DEĞERLENDİRME: MYELODİSPLASTİK SENDROM KONUSU YAYINLARIN GLOBAL ANALİZİ VE TÜRKİYE KAYNAKLI YAYINLARIN DEĞERLENDİRİLMESİ	4
457	Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. 2021 , 6, 323	13
456	Management of the Older Patient with Myelodysplastic Syndrome. 2021 , 38, 751-767	3
455	TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy. 2021 , 43, 917-931	0
454	Pretransplantation Red Blood Cell and Platelet Transfusion Burden in De Novo Myelodysplastic Syndrome Undergoing Allogeneic Transplantation. 2021 , 27, 671-678	1
453	Myelodysplastic Syndromes: A New Decade. 2021 ,	2
452	Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers. 2021 , 5, e632	3
451	Use of Oral Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes. 2021 , 21, S73-S76	
450	Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome. 2021 , 56, 3016-3023	0
449	BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome. 2021 , 22,	2

448	Cell Population Data NE-WX, NE-FSC, LY-Y of Sysmex XN-9000 can provide additional information to differentiate macrocytic anaemia from myelodysplastic syndrome: A preliminary study. 2021,	0
447	Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. 2021, 56, 3008-3015	0
446	The anemia-independent impact of myelodysplastic syndromes on health-related quality of life. 2021, 100, 2921-2932	0
445	U2af1 is a haplo-essential gene required for hematopoietic cancer cell survival in mice. 2021, 131,	1
444	Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome. 2021,	0
443	Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center. 2021, 108, 106611	1
442	Coexisting primary tumors from esophageal cancer and myelodysplastic syndromes: A case report. 2021, 9, e04872	
441	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. 2021, 137, 31-44	3
440	Mismatch in SIRPB β , a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. 2021, 5, 3407-3417	0
439	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. 2021, 110, 106713	2
438	Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies. 2021, 27, 990-999	
437	Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. 2021, 109, 106625	
436	Prognostic impact of peripheral blood mRNA expression levels in response to azacytidine in MDS: A single-centre analysis. 2021, 15, 100231	
435	Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients. 2021, 100, 1995-2004	1
434	Clinical Response to Traditional Chinese Herbs Containing Realgar (AsS) is Related to DNA Methylation Patterns in Bone Marrow DNA from Patients with Myelodysplastic Syndrome with Multilineage Dysplasia. 2021, 13, 55-63	2
433	Molecular Genetics of Myelodysplastic Syndromes.	1
432	Myelodysplastic Syndromes: Pathophysiology. 77-86	1
431	Concurrent inflammatory bowel disease and myelodysplastic syndromes. 5, 98-103	10

430	Acute Myeloid Leukemia and the Myelodysplastic Syndromes. 2006 , 1160-1181	1
429	Classification and Staging of Myelodysplastic Syndromes. 2006 , 39-53	1
428	Role of hematopoietic stem cell transplantation in acute myelogenous leukemia and myelodysplastic syndrome. 2009 , 144, 415-39	1
427	Advances in the therapy of the myelodysplastic syndromes. 1999 , 99, 335-62	1
426	Evolving concepts in myelodysplastic syndromes. 2001 , 108, 1-24	3
425	Biology of stem and myeloid progenitor cells in myelodysplastic syndromes. 2001 , 108, 45-63	2
424	The monocytic component in myelodysplastic syndromes. 2001 , 108, 81-92	2
423	Molecular, cytogenetic and genetic abnormalities in MDS and secondary AML. 2001 , 108, 111-57	8
422	Allogeneic Hematopoietic Cell Transplantation for Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders. 2008 , 167-182	2
421	Cytogenetics in myelodysplastic syndromes. 2011 , 730, 79-88	2
420	Biology and Pathophysiology of MDS with del(5q). 2020 , 43-54	1
419	Prognostic Models in Myelodysplastic Syndromes. 2020 , 109-127	2
418	Myelodysplastic Syndromes (MDS). 2010 , 153-222	1
417	Pediatric Myelodysplastic Syndromes. 2018 , 57-79	1
416	Myelodysplastic Syndrome. 2018 , 83-98	1
415	Neue Arzneimittel 2009. 2010 , 47-126	2
414	DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. 2000 , 249, 135-64	132
413	Prognostic Scoring in MDS. 2011 , 103-120	2

412	Nuclear phosphoinositides: location, regulation and function. 2012 , 59, 335-61	27
411	Nuclear PI-PLC β and Myelodysplastic syndromes: from bench to clinics. 2012 , 362, 235-45	7
410	Myelodysplastic Syndromes. 2008 , 2235-2259	1
409	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. 2009 , 331-402	1
408	Leukocytic Disorders. 2011 , 601-655	2
407	Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome. 2017 , 23, 2143-2150	13
406	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation. 2020 , 26, 1607-1611	1
405	Myelodysplastic syndrome. 548-570	1
404	Oncogene mutation and prognosis in the myelodysplastic syndromes. 2000 , 111, 873-874	8
403	Myelodysplastic Syndromes. 2020 , 383, 1358-1374	94
402	Myelodysplastic Syndrome and Pregnancy: The Mayo Clinic Experience. 2001 , 42, 1229-1234	8
401	Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. 2020 , 61, 1475-1483	3
400	Smoking and myelodysplastic syndromes. 2000 , 11, 285-91	60
399	U2AF1 is a haplo-essential gene required for cancer cell survival.	1
398	Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes. 2020 , 111, 580-591	19
397	Randomised controlled trial of conditioning regimen for cord blood transplantation for adult myeloid malignancies comparing high-dose cytarabine/cyclophosphamide/total body irradiation with versus without G-CSF priming: G-CONCORD study protocol. 2020 , 10, e040467	3
396	Achievements in Understanding and Treatment of Myelodysplastic Syndromes. 2000 , 2000, 110-132	2
395	Achievements in Understanding and Treatment of Myelodysplastic Syndromes. 2000 , 2000, 110-132	3

394	Novel therapeutic strategies: hypomethylating agents and beyond. 2012 , 2012, 65-73		26
393	Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes. <i>Blood</i> , 1997 , 90, 1403-1409	2.2	13
392	Application of the International Scoring System for Myelodysplasia to M.D. Anderson Patients. <i>Blood</i> , 1997 , 90, 2843-2845	2.2	1
391	Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1998 , 92, 1910-1917	2.2	3
390	The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. <i>Blood</i> , 2000 , 96, 3932-3938	2.2	5
389	Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. <i>Blood</i> , 2000 , 96, 2012-2021	2.2	8
388	Lowering the boom on lower-risk myelodysplastic syndromes. 2019 , 2019, 367-372		1
387	Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia. 2021 , 17, e517-e525		2
386	Myelodysplastic syndromes. 2004 , 669-695		2
385	Tandem triplication of the long arm of chromosome 1, trp(1)(q21q32), in two cases with myelodysplastic syndromes. 2015 , 18, 23-30		1
384	Visualising the cross-level relationships between pathological and physiological processes and gene expression: analyses of haematological diseases. 2013 , 8, e53544		8
383	Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. 2014 , 9, e95473		8
382	Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. 2014 , 9, e100206		35
381	Detection of SRSF2-P95 mutation by high-resolution melting curve analysis and its effect on prognosis in myelodysplastic syndrome. 2014 , 9, e115693		23
380	Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome. 2017 , 12, e0172147		29
379	Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis. 2017 , 12, e0185053		14
378	Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges. 2013 , e256-e270		1
377	Association of loss of heterozygosity with cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome. 2008 , 41, 610-4		2

376	Understanding the Myelodysplastic Syndromes. 1997 , 2, 389-401	32
375	Cellular senescence induced by S100A9 in mesenchymal stromal cells through NLRP3 inflammasome activation. 2019 , 11, 9626-9642	19
374	Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. 2010 , 1, 34-42	99
373	Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). 2016 , 7, 63177-63188	13
372	Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality. 2016 , 7, 72685-72698	16
371	Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes. 2017 , 8, 1603-1612	5
370	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. 2017 , 8, 37866-37874	8
369	Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup. 2017 , 8, 79188-79200	5
368	Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis. 2017 , 8, 43295-43305	15
367	BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. 2017 , 8, 47103-47109	13
366	Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. 2017 , 8, 81926-81935	11
365	Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). 2010 , 1, 483-496	42
364	Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. 2014 , 5, 4384-91	13
363	Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. 2017 , 8, 88904-88917	28
362	Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. 2017 , 8, 103274-103282	12
361	Reactive oxygen species levels control NF- κ B activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. 2017 , 8, 105510-105524	25
360	Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes. 2017 , 8, 115002-115017	5
359	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. 2018 , 9, 9714-9727	42

358	Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile. 2018 , 9, 17270-17281	8
357	Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients. 2018 , 9, 36929-36944	10
356	The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes. 2019 , 10, 2270-2281	4
355	Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. 2015 , 6, 9612-26	125
354	Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome. 2015 , 6, 35095-106	7
353	Effect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes. 2016 , 7, 27479-88	1
352	Prognostic Value of Next-Generation Sequencing Data in Patients with Myelodysplastic Syndrome. 2020 , 13, 170-175	1
351	Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes. 2006 , 2, 377-88	65
350	Outcome After Azacitidine Treatment in Patients with High-Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia [A Single Center Experience (Preliminary Data)]. 2020 , 47, 38-43	1
349	Myelodysplastic syndromes: moving towards personalized management. 2020 , 105, 1765-1779	21
348	Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome. 2020 , 105, 2785-2794	19
347	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. 2020 , 105, 2516-2523	3
346	Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement. 2020 , 17,	0
345	A CASE OF AORTIC VALVE REPLACEMENT IN A PATIENT WITH MYELODYSPLASTIC SYNDROME AND AORTIC VALVE STENOSIS. 2010 , 71, 2825-2829	1
344	Usefulness of Adalimumab for Treating a Case of Intestinal Behçet's Disease With Trisomy 8 Myelodysplastic Syndrome. 2015 , 13, 166-9	21
343	Signal Detection on the Concomitant Use of Deferasirox with other Drugs and Acute Renal Failure Using Data Mining of the Japanese Adverse Drug Event Report Database and Evaluation by a Case-control Study. 2016 , 42, 717-726	3
342	CD34/QBEND10 immunostaining in the bone marrow trephine biopsy: a study of CD34-positive mononuclear cells and megakaryocytes. 2002 , 126, 823-8	15
341	Myelodysplastic syndromes: clinicopathologic features, pathobiology, and molecular pathogenesis. 2005 , 129, 1299-310	21

340	Myelodysplastic syndromes in children: a critical review of issues in the diagnosis and classification of 887 cases from 13 published series. 2007 , 131, 1110-6	31
339	Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. 2010 , 134, 1010-5	39
338	Revisiting use of growth factors in myelodysplastic syndromes. 2012 , 13, 1081-91	10
337	Current Management and New Developments in the Treatment of Myelodysplastic Syndrome. 2021 , 181, 115-132	
336	Impact of next generation sequencing results on clinical management in patients with hematological disorders. 2021 , 62, 1702-1710	1
335	Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine. 2021 , 10,	
334	Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. 2021 ,	0
333	A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes. 2021 , 5, 4535-4548	2
332	Meaningful response criteria for myelodysplastic syndromes. 2021 ,	1
331	MYC overexpression is associated with an early disease progression from MDS to AML. 2021 , 111, 106733	0
330	Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?. 2021 , 17, 5163-5175	0
329	Non-Ablative Chemotherapy Followed by HLA-Mismatched Allogeneic CD3 T-Cells Infusion Causes An Augment of T-Cells With Mild CRS: A Multi-Centers Single-Arm Prospective Study on Elderly Acute Myeloid Leukemia and int-2/High Risk Myelodysplastic Syndrome Patients. 2021 , 11, 741341	
328	Myelodysplastische Syndrome. 2000 , 910-922	
327	Myelodysplasia and Acute Leukemia Following High-Dose Chemotherapy. 2000 , 261-277	
326	Myelodysplastic Syndromes. 2000 , 147-156	
325	Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. <i>Blood</i> , 2000 , 95, 3273-3279	2.2 1
324	Validation of the IPSS and Other Scoring Systems in Patients with Primary MDS. 2001 , 169-171	
323	Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes. 2001 , 649-654	

322 Colony Stimulating Factors in Myelodysplastic Syndromes. **2001**, 210-217

321 Use of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. **2002**, 235-239

320 Myelodysplastisches Syndrom und akute myeloische Leukämie. **2002**, 389-419

319 Current status and future developments of rhEPO in clinical oncology. **2002**, 447-492

318 Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia. **2003**, 13-27

317 Myelodysplastische Syndrome. **2003**, 1038-1046

316 Myelodysplastic Syndromes. **2003**, 243-253

315 Intensification of the Conditioning Regimen for Patients with high-risk AML and MDS: 3 year Experience of using an¹⁸⁸Re [Labelled anti CD 66 Monoclonal Antibody. **2003**, 43-58

314 Myelodysplastische Syndrome. **2003**, 268-311

313 Telomeres in Myelodysplastic Syndrome and Its Related Disorders: Does Telomere Length Reflect Stem Cell Turnover in Clonal Hematopoietic Disorders?. **2003**, 167-178

312 The New WHO Classification for Akute Myeloid Leukemias and Myelodysplastic Syndromes. **2003**, 3-6

311 Myelodysplastische Syndrome. **2004**, 1815-1846

310 New Applications of Flow Cytometry in Cancer Diagnosis and Therapy. **2004**, 199-232

309 Molecular Pathology of Hematological Malignancies. **2004**, 239-277

308 Acute Myeloid Leukemia. **2004**, 179-214

307 [Isolated central nervous system angiitis and myelodysplastic syndrome: case report]. **2004**, 62, 555-7

306 DNA Demethylating Agents. **2004**, 183-212

1

305 Acquired genetic changes in myeloid malignancies. **2004**, 218-233

304 Myelodysplastic Syndrome Risk Class Analysis by Microarray. **2004**, 881-884

303 Profile of azacitidine. **2005**, 2, 717-731

1

302 Zyto- und molekulargenetische Anomalien bei malignen Erkrankungen. **2006**, 46-92

301 Cytogenetic Diagnosis of Myelodysplastic Syndromes. **2006**, 55-79

300 Myelodysplastisches Syndrom (MDS). **2006**, 2724-2748

299 Management of Patients with Myelodysplastic Syndromes: Introductory Concepts. **2006**, 89-94

298 Hemopoietic Cell Transplantation. **2006**, 123-134

297 CLINICOPATHOLOGICAL FEATURES OF NIGERIANS WITH MYELODYSPLASTIC SYNDROMES. **2006**, 3,

296 Myelodysplastische Syndrome (MDS). **2007**, 359-376

295 Therapy-related AML. **2007**, 71-95

294 References. **2007**, 929-950

1

293 Myelodysplastic Syndromes. **2008**, 529-534

292 Recombinant human erythropoietin (rhEPO) therapy in myelodysplasia. **2008**, 531-539

291 Applications and Outcomes of Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation. **2008**, 319-328

290 Diagnostic Value II: Hematopoietic Malignancies. **2009**, 211-224

289 Telomere and Telomerase for the Regulation of Stem Cells. **2009**, 123-134

288 Pattern-selection based power analysis and discrimination of low- and high-grade myelodysplastic syndromes study using SNP arrays. **2009**, 4, e5054

287 Allogeneic Transplantation for Myelodysplastic Syndromes. **2010**, 203-217

286 Molecular Pathogenesis of Myelodysplastic Syndromes. **2010**, 417-427

285 Chromosomal Abnormalities in Selected Hematopoietic Malignancies Detected by Conventional and Molecular Cytogenetics: Diagnostic and Prognostic Significance. **2010**, 89-113

284 Chronic Myelomonocytic Leukemia (CMML). **2010**, 223-233

283 Molecularly Targeted Therapies in Pediatric Myelodysplastic Syndromes. **2010**, 155-176

282 Retrospective Analysis of 50 Cases of First Allogeneic Transplantation for Acute Myelogenous Leukemia and High Risk Myelodysplastic Syndrome. **2010**, 59, 105-113

281 Hemoglobin Fluctuations and Correlation with Quality of Life and Fatigue. **2010**, 1867-1879

280 Pre-transplant Evaluation. **2010**, 27-37

279 Acute and Chronic Leukemias. **2010**, 529-570

278 Chronic Leukemias. **2010**, 610-615

277 The Myelodysplastic Syndromes. **2010**, 606-609

276 Myelodysplastic Syndromes and Chronic Myeloproliferative Neoplasms. **2010**, 293-312

275 Myelodysplastic Syndromes in the Senior Patient. **2010**, 82-91

274 Haemopoietic effects of workplace exposures. **2010**, 1215-1229

273 The Myelodysplastic Syndromes. 503-529

272 Serial Determination of FLT3-ITD and NPM1 Mutations and Its Clinical Significance in Patients with MDS at Diagnosis and After Progression to AML with Myelodysplasia-related Changes. **2011**, 1, 138

271 The Myelodysplastic Syndromes. **2011**, 656-671

270 Diagnostic Criteria and Classification of Myelodysplastic Syndromes. **2011**, 43-53

1

269 Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical Features and Standard Evaluation. **2011**, 25-41

2

- 268 Encyclopedia of Cancer. **2011**, 2433-2436
- 267 A Case Of Anemia and Thrombocytopenia with Myelodysplastic Syndrome Successfully Treated with Juzentaihoto and Malt Sugar. **2011**, 62, 363-368 2
- 266 Myelodysplastic Syndromes. 99-114
- 265 Myelodysplastic Syndromes: The Role of Cytogenetic and Molecular Abnormalities for Classification and Risk Assignment. 87-98
- 264 Hämatologische und onkologische Erkrankungen. **2011**, 607-718
- 263 JMML and Myelodysplastic Syndrome in Children. **2011**, 253-278
- 262 Cytogenetic Analysis and Related Techniques in Hematopathology. **2011**, 81-94 1
- 261 The History of the Myelodysplastic Syndromes. **2011**, 1-4 1
- 260 Traitement des syndromes myélodysplasiques. **2011**, 757-768
- 259 Cytokines in MDS: Abnormalities and Treatment. **2011**, 205-218
- 258 Therapeutic Modalities and New Molecular Targets in MDS. **2011**, 219-238
- 257 The Myelodysplastic Syndromes. 219-260
- 256 Supportive Care in Myelodysplastic Syndrome. 172-190
- 255 Myelodysplastic Syndrome: A Review of Current Care. 153-171
- 254 Myeloproliferative Neoplasms and Myelodysplastic Syndromes. 220-234
- 253 Myelodysplastic Syndromes (MDS). **2012**, 149-168
- 252 Use of rHuG-CSF in Myelodysplastic Syndromes. **2012**, 183-193 1
- 251 Myelodysplasia and Myeloid Proliferations. **2012**, 75-100

- 250 A case of synchronous double cancer of the stomach and the ascending colon associated with myelodysplastic syndrome. **2012**, 73, 502-508 2
- 249 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61
- 248 Molecular Biology of Myelodysplastic Syndromes. **2012**, 117-127
- 247 A woman in her seventies with reduced general condition, dyspnoea and generalised pain. **2012**, 132, 1969-72 3
- 246 A myelodysplastic syndrome with early gastric cancer and early colon cancer : case report. **2012**, 81, 112-113 1
- 245 Myelodysplastic Syndromes. **2012**, 523-546
- 244 Hematology. **2012**, 767-871
- 243 Myelodysplastic Syndromes. **2012**, 203-240
- 242 Erythropoiesis-stimulating agents for myelodysplastic syndromes.
- 241 Lymphoid and Hematopoietic Systems. **2013**, 145-158
- 240 Epidemiology and Etiology. **2013**, 9-38
- 239 Management of High-Risk Myelodysplastic Syndrome. **2013**, 189-210
- 238 Immunophenotyping in Myelodysplastic Syndromes. **2013**, 141-152
- 237 A Personalized Molecular Pathogenesis of MDS. **2013**, 97-109
- 236 Prognostic Models for Patients with Myelodysplastic Syndromes. **2013**, 153-167
- 235 Hematopoietic Cell Transplantation (HCT). **2013**, 211-228
- 234 Classification and Staging of Myelodysplastic Syndromes. **2013**, 127-139
- 233 Lenalidomide for patients with red blood cell transfusion-dependent low- or intermediate-1-risk IPSS myelodysplastic syndromes.

- 232 The Myelodysplastic Syndromes: Pathophysiology, Care and Management. 171-182
- 231 PTK2 and PTPN11 expression in myelodysplastic syndromes. **2013**, 68, 1371-5
- 230 Thrombocytosis. **2014**, 133-150
- 229 Leukemias, Lymphomas, and Other Related Disorders. **2014**,
- 228 Molecular Testing in Hematologic Malignancies. **2014**, 135-167
- 227 Myelodysplastic Syndromes. **2014**, 1907-1928.e8
- 226 Hematopoietic Stem Cell Transplantation. **2014**, 485-492.e2
- 225 Myelodysplastische Syndrome. **1998**, 155-164
- 224 Myelodysplastic Syndromes. **1999**, 382-398
- 223 Myelodysplastische Syndrome. **1999**, 953-957
- 222 Cytokines for the Treatment of Myelodysplastic Syndromes and Other Bone Marrow Failure States. **1999**, 326-339
- 221 Myelodysplastic Syndromes in Older Patients. **2015**, 49-61
- 220 XRCC1 Arg194Trp and XRCC1 Arg399Gln Polymorphisms Affect Clinical Features and Prognosis of Myelodysplastic Syndromes. **2015**, 65, 11-19
- 219 Myelodysplastische Syndrome (MDS). **2015**, 1-6
- 218 A Case of Papillary Thyroid Carcinoma Complicated with Myelodysplastic Syndrome Who Underwent Carotid Artery Reconstruction. **2015**, 66, 284-290
- 217 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79
- 216 Myelodysplastische Syndrome. **2016**, 1-9
- 215 Myelodysplastic syndromes in 2016. **2016**, 10, 114-119

214 <http://ajbm.net/952016-2/>. **2016**, 4, 360-363

213 XRCC1 Arg194Trp and XRCC1 Arg399Gln Polymorphisms Affect Clinical Features and Prognosis of Myelodysplastic Syndromes. **2017**, 67, 93-94

212 Epigenetic Regulator, Re-emerging Antimetabolites with Novel Mechanism of Action (Azacitidine and Decitabine): Clinical Pharmacology and Therapeutic Results. **2017**, 327-340

211 Myelodysplastische Syndrome. **2017**, 1-15

210 Myelodysplastic Syndromes. **2017**, 1-4

209 Cord Blood Transplants for Myeloid Malignancies in Adults. **2017**, 163-179

208 [Analysis of VEGF-A/VEGFR1/VEGFR2 gene expression in patients with myelodysplastic syndrome]. **2017**, 89, 39-44

207 Myelodysplastic Syndromes. **2018**, 239-242

206 Myelodysplastische Syndrome. **2018**, 183-197

205 A perspective of novel treatment strategy for myelodysplastic syndrome. **2018**, 107, 1566-1572

204 Clonal Hematopoiesis and Cytopenias in the Elderly. **2019**, 195-212

203 Elderly Gastric Cancer Patients with Myelodysplastic Syndrome. **2018**, 51, 688-693

202 Bone Marrow Malignancies and Indications for Hematopoietic Cell Transplantation. **2019**, 387-400

201 Myelodysplastic Syndromes. **2019**, 547-556

200 Myelodysplastic Syndromes. **2019**, 913-942

199 Myelodysplastic Syndrome. **2019**, 1-21

198 Myelodysplastic Syndrome: An Overview. **2019**, 149-161

197 Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic Syndrome. **2019**, 12, 120-124

196 Profiling Myelodysplastic Syndromes by Mass Cytometry Demonstrates Abnormal Progenitor Cell Phenotype and Differentiation.

195 Mersin Bölgesinde Yaşayan Yüksek Riskli Myelodisplastik Sendrom Hastalarında Kronik Hastalık Varlığının Sağlık Kalitesine Etkisi.

194 Non-canonical immune response to the inhibition of DNA methylation via stabilization of endogenous retrovirus dsRNAs.

193 TP53 in Myelodysplastic Syndromes. **2021**, 13,

1

192 Myelodysplastic Syndrome. **2020**, 479-499

191 HSCT in Malignancies. **2020**, 1-16

190 Treatment Algorithms for Lower-Risk Myelodysplastic Syndrome. **2020**, 131-145

189 Syndromes myélodysplasiques et leucémies aiguës. **2020**, 270-278.e3

188 Advances in Acute Myeloid Leukemia Management: Focus on Secondary Disease and Older Patients. **2020**, 18, 1785-1787

187 Some characteristics of patients with myelodysplastic syndrome. **2020**, 11, 32-42

186 Morphological, Flow Cytometry, and Cytogenetic Diagnosis of MDS. **2020**, 19-42

o

185 Molecular Landscape of MDS. **2020**, 73-90

184 Myelodysplastic/Myeloproliferative Neoplasms. **2020**, 559-594

183 ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. **2020**, B-1-B30-3

182 Evolutionary Action Score of TP53 Mutations: Integrated Clinico-pathologic And Protein Structural Analysis in Myelodysplastic Syndromes.

181 Myelodysplastische Syndrome. **2005**, 1090-1098

180 Tumors of the Lymphoid and Hematopoietic Systems. **2007**, 82-90

179 Bone Marrow Failure Syndromes. **2006**, 862-870

178 Myelodysplastic Syndromes. **2007**, 195-205

177 Antiangiogenic Agents in Myeloid Malignancies. **2008**, 457-473

176 Targeted Therapy in Myelodysplastic Syndrome. **2008**, 237-260

175 Hochdosistherapien. 143-194

174 Myelodysplastische Syndrome. 227-238

173 Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes. **2021**, 13, 2

172 Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study. **2021**, 2

171 Clinical, Pathological and Molecular Features of Myelodysplasia Cutis. *Blood*, **2021**, 2.2 0

170 Percutaneous left atrial appendage closure in patients with primary hemostasis disorders and atrial fibrillation. **2021**, 1 0

169 Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients. **2021**, 12, 1019-1030 0

168 Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure. 52-64

167 Is 5q deletion in de novo Acute Myelogenous Leukemia (AML) with excess blasts a surrogate marker for the cryptic t(7;21)(p22;q22)? A case report and review of literature.. **2021**, 262-263, 30-34

166 Myelodysplastic Syndromes. **2020**, 107-126

165 BMT for Myelodysplastic Syndrome: When and Where and How.. **2021**, 11, 771614 0

164 How low risk are low risk myelodysplastic syndromes?. **2022**, 1

163 What are the risks and benefit of a transplant for elderly patients?. **2022**, 11, 22-35

162 Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.. **2022**, 148, 845 0

161 Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. **2021**, 2

- 160 Hematopoietic cell transplantation for myelodysplastic syndromes. **2022**, 11, 43-52
- 159 Heightened NLRP3 inflammasome activation is associated with aging and CMML diseases severity.
- 158 Dysregulation of immune cell and cytokine signaling correlates with clinical outcomes in myelodysplastic syndrome (MDS).. **2021**,
- 157 The FLT3 internal tandem duplication mutation at disease diagnosis is a negative prognostic factor in myelodysplastic syndrome patients.. **2022**, 113, 106790
- 156 The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis.. **2022**, 1-9 2
- 155 Historical expectations with DNMT1 monotherapy in MDS: When is combination therapy truly 'promising'?. **2022**, 0
- 154 Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes.. **2021**, 10, 1
- 153 Myelodysplasia. **2022**, 316-330
- 152 Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT.. **2022**, 0
- 151 Concurrent ankylosing spondylitis and myelodysplastic syndrome: A case report.. **2022**, 10, 1929-1936
- 150 Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes.. **2022**, 23, 0
- 149 Myeloablative versus reduced-intensity conditioning with fludarabine/busulfan for myelodysplastic syndrome: A propensity score-matched analysis.. **2022**, 0
- 148 Phase 1/2 Study Evaluating the Safety and Efficacy of DSP-7888 Dosing Emulsion in Myelodysplastic Syndromes.. **2021**, 1
- 147 Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes.. **2022**, 11, 0
- 146 Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience.. **2022**, 12, 795955 0
- 145 Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.. **2022**, 1
- 144 Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes.. **2022**, 12, 846044 0
- 143 Txnip Enhances Fitness of Dnmt3a-Mutant Hematopoietic Stem Cells via p21.. **2022**, OF1-OF20 4

142	Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes.. 2022 , 12, 5925	0
141	Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the erythropoietic niche.. 2022 ,	1
140	Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis.. 2022 ,	0
139	Interleukin-1 (IL-1) and the inflammasome in cancer.. 2022 , 153, 155850	6
138	Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials.. 2021 , 17, 307-314	0
137	Have we reached a molecular era in myelodysplastic syndromes?. 2021 , 2021, 418-427	2
136	Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.. 2021 , 1-11	
135	Prognostic Risk Factors in Myelodysplastic Syndromes in Adults. 2020 , 347-356	
134	New Approaches to Myelodysplastic Syndrome Treatment.. 2022 ,	1
133	A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.. 2022 ,	0
132	Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS).. 2022 , 14,	0
131	The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).. 2022 ,	1
130	Next Generation Risk Markers in Preventive Cardio-oncology.. 2022 , 1	0
129	Bone marrow. 813-942	
128	Myelodysplastic syndromes (MDS). 103-115	
127	Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes.. 2022 , 1	
126	Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes. 2022 ,	
125	Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.. 2022 , 1	1

124	RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.. 2022 ,	2
123	Hematological Diseases. 2022 , 73-120	
122	Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents: A Prospective Cohort Study of the AGMT Study-Group. 2022 , 14, 2459	2
121	The Prognostic Value of Pretherapy Peripheral Blood Inflammatory Indices in Myelodysplastic Syndromes.. 2022 , 12, 877981	
120	Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome.	0
119	Bone marrow fibrosis impact on response to azacitidine in myelodysplastic syndromes. 2022 ,	
118	Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation. 2022 , 27, 620-628	
117	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan + clofarabine in allogeneic stem cell transplantation.	
116	Azacitidine and its role in the upfront treatment of acute myeloid leukemia. 2022 , 23, 873-884	0
115	Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum.	0
114	A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low or intermediate-1 risk myelodysplastic syndrome.	0
113	IDH2: A novel biomarker for environmental exposure in blood circulatory system disorders (Review). 2022 , 24,	0
112	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.	21
111	Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis. <i>Blood</i> ,	2.2 0
110	Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers. 2022 , 12, 1556	1
109	A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm. 2022 , 27, 129-138	0
108	Myelodysplastic syndrome: epidemiology, diagnostics and epigenetic disorders. 2022 , 13, 179-190	
107	Myelodysplastic Syndrome: Diagnosis and Screening. 2022 , 12, 1581	

- 106 Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. *Blood*, 2022, 137, 2222-2231. 2.2 2
- 105 Past, present and future in low-risk myelodysplastic syndrome. 9, 2022, 1-10
- 104 ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial. 2022, 137, 2222-2231
- 103 Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation Supported by Third-Party Cord Blood Versus Human Leukocyte Antigen-Matched Sibling Peripheral Blood Stem Cell Transplantation in Hematologic Malignancy Patients. 12, 2022, 1-10
- 102 Prognostic value of the controlling nutritional status score in patients with myelodysplastic syndromes. 9, 2022, 1-10
- 101 SOHO State of the Art & Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes. 2022, 137, 2222-2231
- 100 In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia: A Narrative Review of Current Knowledge. 2022, 11, 4283
- 99 Association between transfusion status and clinical and economic outcomes in patients with myelodysplastic syndromes from the physicians' perspective. 2022, 137, 2222-2231
- 98 Lower-risk myelodysplastic syndromes: Current treatment options for anemia. 2022, 137, 2222-2231 1
- 97 Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study). 2022, 137, 2222-2231
- 96 Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis. 12, 2022, 1-10
- 95 Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment. 13, 2022, 1-10
- 94 Higher RUNX1 expression levels are associated with worse overall and leukaemia-free survival in myelodysplastic syndrome patients. 2022, 137, 2222-2231
- 93 Leukemias, Lymphomas, and Plasma Cell Disorders. 2023, 237-300
- 92 Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1b study. 2022, 9, e756-e765 2
- 91 MORPHOLOGICAL FEATURES OF BONE MARROW IN PATIENTS WITH MYELODYSPLASTIC SYNDROME (literature review). 2012, 14-18
- 90 IPSS-M Incorporates Next-Generation Sequencing for a New International Prognostic Scoring System. 2022, 19, 2022, 1-10
- 89 Myelodysplastic Syndrome: A Real-World Experience from a Developing Country. 2022, 137, 2222-2231

88	Causes and Pathophysiology of Acquired Sideroblastic Anemia. 2022 , 13, 1562	0
87	SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome. 2022 ,	1
86	Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study.	0
85	IMMUNE DEREGLATION IN MYELOYDYSPLASTIC SYNDROMES - THE ROLE OF CYTOKINES AND SOLUBLE ADHESION MOLECULES. A PILOT STUDY.	0
84	Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients.	0
83	Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory. 2022 , 22,	0
82	IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons \geq 60 years with myelodysplastic syndromes.	0
81	Diagnosis and Treatment of Myelodysplastic Syndromes. 2022 , 328, 872	2
80	Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes.	0
79	Flow cytometry lyophilised-reagent tube for quantifying peripheral blood neutrophil myeloperoxidase expression in myelodysplastic syndromes (MPO-MDS-Develop): protocol for a diagnostic accuracy study. 2022 , 12, e065850	0
78	Therapy related myeloid neoplasms following PARP inhibitors: real-life experience.	0
77	Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations. 2022 ,	0
76	The Seeds of Progression From Myelodysplastic Syndrome to Acute Myeloid Leukemia Are Sown Early in the Course of Disease. 2022 , 19,	0
75	Treatment of higher-risk myelodysplastic syndrome. 2022 , 75, 38-43	0
74	Diagnosis, classification, and prognosis of myelodysplastic syndromes. 2022 , 75, 25-31	0
73	Hematopoietic Cell Transplantation. 1-13	0
72	Allogeneic stem cell transplantation for patients with myelodysplastic syndromes.	0
71	Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation. 2022 , 12, 2493	0

70	Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome. 2022 , 12,	0
69	IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥60 years with myelodysplastic syndromes. 2022 , 11,	0
68	Lenalidomide and Eltrombopag for Treatment of Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Clinical Trial.	0
67	Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes. 2022 , 14, 4941	0
66	How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms. 2022 , 101405	0
65	Improving clinical trials in higher-risk myelodysplastic syndromes. 2022 , 101406	0
64	Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial.	0
63	Myelodysplastic Syndromes. 1-20	0
62	Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia. 12,	0
61	Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome.	0
60	Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.	0
59	Over expression of mTOR gene predicts overall survival in myelodysplastic syndromes.	0
58	How Can We Incorporate Molecular Data into the IPSS?. 2022 , 101410	0
57	Molecular patterns identify distinct subclasses of myeloid neoplasia.	0
56	Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment. 2022 , 156, 113905	0
55	MODERN PRINCIPLES OF CLASSIFICATION, PROGNOSIS AND TREATMENT OF PRIMARY MYELODYSPLASTIC SYNDROMES. 2011 , 34-41	0
54	Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age. 2022 , 101033	1
53	Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment. 2022 , 14, 5531	0

52	Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.	0
51	Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine. 1-15	0
50	Myelodysplastic syndromes. 2022 , 8,	0
49	New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome. 2022 , 17, 106-117	0
48	Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS.	0
47	Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-Risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-Analysis. 2022 ,	1
46	Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS/sAML: A monocentric real-world experience. 2023 , 124, 106996	0
45	Management of Adult Patients with Myelodysplastic Syndromes. 104-112	0
44	When clinico-morphological and molecular studies tell different stories: A case of myelodysplastic syndrome. 2022 , 12, 288	0
43	The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms. 2022 , 14, 5690	1
42	Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. 2022 ,	0
41	Therapeutic approaches for the management of higher risk myelodysplastic syndromes. 1-14	0
40	Management of patients with lower-risk myelodysplastic syndromes. 2022 , 12,	1
39	Role of Bcl-2 inhibition in myelodysplastic syndromes.	0
38	Fetal hemoglobin level predicts lower-risk myelodysplastic syndrome.	0
37	Long-term outcomes of aplastic anemia with cytogenetic abnormalities at diagnosis.	0
36	All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RAR β -Nrf2 complex.	0
35	Contingent Synergistic Interactions between Non-Coding RNAs and DNA-Modifying Enzymes in Myelodysplastic Syndromes. 2022 , 23, 16069	0

34	State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes. 2023,	0
33	Analysis of Immune-Cell Distribution of Bone Marrow in Patients with Myelodysplastic Syndrome. 2023, 15, 50-56	0
32	Advances in myelodysplastic syndromes: promising novel agents and combination strategies. 1-13	1
31	Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway. 2023, 28,	0
30	Clinical significance of prognostic nutritional index in myelodysplastic syndrome. 2023, 28,	0
29	Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice. 1-12	0
28	Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes. 2023, 24, 463	1
27	How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.	1
26	The effects of mean platelet volume and red cell distribution width on prognosis in patients with myelodysplastic syndrome. 59-64	0
25	Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?.	0
24	Myelodysplastic syndromes, thy name is heterogeneity.	0
23	The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms. 2023, 98,	0
22	Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes [A potential prognostic marker?]. 12,	0
21	Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS.	0
20	Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes. 2023, 13,	0
19	Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression. 2023, 37, 680-690	0
18	Molecular Drivers of Myelodysplastic Neoplasms (MDS) Classification and Prognostic Relevance. 2023, 12, 627	0
17	A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome. 2023, 12, 633	0

- 16 Extracellular Vesicles and MicroRNA in Myelodysplastic Syndromes. **2023**, 12, 658 ○
- 15 Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. ○
- 14 Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine: A Prospective Cohort Study by the AGMT. **2023**, 15, 1388 ○
- 13 Appropriate pre-transplant strategy for patients with myelodysplastic syndromes receiving allogeneic haematopoietic stem cell transplantation after myeloablative conditioning. 14, ○
- 12 Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases. **2023**, 15, 180-187 ○
- 11 Sequential vs Myeloablative vs Reduced Intensity Conditioning for Patients with Myelodysplastic Syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A Retrospective Study by the Chronic Malignancies Working Party of the EBMT. ○
- 10 Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database. **2023**, 102, 1215-1227 ○
- 9 The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients: a randomized trial. **2023**, 37, 807-819 ○
- 8 The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia. **2023**, 24, 5734 ○
- 7 Efficacy and safety of Sanzi-huangshi pill as an adjuvant therapy in lower-risk myelodysplastic syndrome: study protocol for a multi-center randomized controlled trial. ○
- 6 Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndromes Defined by International Consensus Classification. ○
- 5 Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis. ○
- 4 Raising the bar for lower-risk myelodysplastic syndromes. 1-10 ○
- 3 Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome. ○
- 2 Myelodysplastic Syndrome: Approach to Diagnosis in the Era of Personalized Medicine. **2023**, ○
- 1 Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes. ○